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Trupti Shetty 
THE ROLE OF HEME SYNTHESIS IN ENDOTHELIAL MITOCHONDRIAL 
FUNCTION AND OCULAR ANGIOGENESIS 
Abnormal blood vessel growth from pre-existing blood vessels, termed 
pathological angiogenesis, is a common characteristic of vascular diseases like 
proliferative diabetic retinopathy (PDR) and wet age-related macular 
degeneration (wet AMD). Retinal detachment, hemorrhage, and loss of vision are 
only some of the debilitating consequences of advanced pathological 
angiogenesis. Current therapeutics targeting these blood vessels are ineffective 
in many patients. We previously identified a novel angiogenesis target, 
ferrochelatase (FECH), from the heme synthesis pathway, and found that FECH 
inhibition is antiangiogenic in cell and animal models. Heme synthesis occurs in 
mitochondria, where FECH inserts Fe2+ into protoporphyrin IX (PPIX) to produce 
heme. However, the relationship between heme metabolism and angiogenesis is 
poorly understood.  
I sought to understand the mechanism of how FECH and thus, heme is 
involved in endothelial cell function. First, I determined the energetic state of 
retinal and choroidal endothelial cells, previously uncharacterized. I found that 
mitochondria in endothelial cells had several functional defects after heme 
inhibition. FECH loss changed the shape of mitochondria and depleted 
expression of genes maintaining mitochondrial dynamics. FECH blockade 
elevated oxidative stress and depolarized mitochondrial membrane potential. 
Heme depletion had negative effects on cellular metabolism, affecting oxidative 
 viii 
phosphorylation and glycolysis. Mitochondrial complex IV of the electron 
transport chain (cytochrome c oxidase) was decreased in cultured human retinal 
endothelial cells and in murine retina ex vivo after FECH inhibition. 
Supplementation with heme partially rescued phenotypes of FECH blockade. 
Additionally, I discovered that partial loss-of-function Fech mutation in mice 
caused PPIX accumulation with no change in normal vasculature, as assessed 
by fundoscopy. These findings provide an unexpected link between mitochondrial 
heme metabolism and angiogenesis. My studies identify a novel role of a heme 
synthesis enzyme in blood vessel formation and provide an opportunity to exploit 
these findings therapeutically for patients with PDR and wet AMD. 
  
Timothy W. Corson, Ph.D., Chair 
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CHAPTER 1. INTRODUCTION 
1.1 Angiogenesis in Health and Disease 
1.1.1 Process of Angiogenesis 
The formation of new blood vessels from pre-existing blood vessels is 
termed as angiogenesis. Endothelial cells (EC) lining the inner walls of these 
small blood vessels drive the process of angiogenesis (Carmeliet and Jain, 2011; 
Vandekeere et al., 2015). This is different from vasculogenesis, in which new 
blood vessel formation arises from endothelial progenitor cells. While the balance 
of both these processes governs growth of blood vessels for embryogenesis and 
wound repair, severe dysregulation of angiogenesis contributes to many 
disorders like malignant tumors, inflammation, neovascular blindness, and 
ischemia (Timar et al., 2001; Carmeliet, 2003). In some cases, excessive 
angiogenesis contributes to disorders like arthritis, cancer, and blindness. 
However, inadequate blood vessel growth has also been recognized as causes 
of cardiac and brain ischemia, neurodegeneration, and osteoporosis (Krupinski et 
al., 1994; Martinez et al., 2002; Jefferies et al., 2013). 
In healthy adults, ECs performing angiogenesis remain quiescent and 
exhibit little proliferation, once vessel formation is complete (Engerman et al., 
1967). ECs are activated in processes like wound healing, endometrium 
formation during menstruation and hair follicular growth (Yano et al., 2001). 
Angiogenesis involves three important features of ECs – proliferation, migration 
and “sprouting” of new vessels. The process begins with dilation of blood vessels 
and an increase in vascular permeability. ECs need to migrate and form tubes, 
which is often accompanied by degradation of surrounding extracellular matrix 
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proteins. The expression of genes required for this proteolytic activity is induced 
by various angiogenic growth factors and cytokines, depending on the tissue and 
vascular network (Figure 1.1). For example, a hypoxic angiogenic stimulus was 
found to increase expression of a major angiogenic growth factor, vascular 
endothelial growth factor A (VEGF-A), which in turn caused increased expression 
of matrix metalloproteinases 9 (MMP-9) (Hollborn et al., 2007). Angiogenesis is, 
thus, a multifactorial process involving a combined effort of many different 
positive and negative regulators.  
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Figure 1.1. Steps in angiogenesis. (Adapted from Bryan BA, D'Amore PA. What 
tangled webs they weave: Rho-GTPase control of angiogenesis. Cell Mol Life 
Sci. 2007 Aug;64(16):2053-65) 
 
Some pro-angiogenic factors are VEGF-A, transforming growth factor beta 
(TGF-β), interleukin-8 (IL-8), among others (Ferrara, 1999). TGF-β promotes 
VEGF-A induced angiogenesis, by initiating apoptosis of ECs which is critical for 
this step. Apoptosis in ECs during angiogenesis enables pruning of the growing 
neovessels and ensures inhibition of abnormal vessels (Ferrari et al., 2009). IL-8 
promotes EC proliferation, survival and tube formation, and induces expression 
of MMPs (Li et al., 2003). Some endogenous anti-angiogenic mediators include 
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angiostatin, endostatin, and pigment-derived factor (PEDF) (Talks and Harris, 
2000). Angiostatin and endostatin inhibit EC proliferation and migration during 
angiogenesis (Moser et al., 1999; Wickstrom et al., 2005), whereas PEDF inhibits 
binding of VEGF to VEGFR, preventing angiogenesis (Cai et al., 2006). In order 
to prevent pathological angiogenesis, a balance is maintained between pro-
angiogenic mediators and anti-angiogenic factors. As a result, stable vessels are 
formed, with a monolayer of ECs lining the lumen, intact junctional proteins, and 
surrounded by pericytes.   
 
1.1.2 Molecular Mechanisms of Angiogenesis 
The vascular endothelial growth factor family includes VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, VEGF-E and placental growth factor (PIGF) (Olofsson et al., 
1998; Persico et al., 1999). Among these, VEGF-A is considered a master 
regulator, widely studied and commonly found in many different diseases of 
pathological angiogenesis like diabetic retinopathy and macular degeneration. 
(Melincovici et al., 2018). VEGF-A has eight exons that have splice variants 
leading to four isoforms – VEGF121, VEGF165, VEGF189 and VEGF206, with 
VEGF165 being the most physiologically relevant isoform (Ferrara et al., 2003). 
VEGFs carry out signal transduction by binding to one of the three members of 
the VEGFR tyrosine kinase receptor family, namely, VEGFR-1, VEGFR-2, and 
VEGFR-3 (Veikkola and Alitalo, 1999; Lohela et al., 2009). During angiogenesis, 
ECs are classically known to be activated by binding of VEGF-A to VEGFR-2 and 
initiate a downstream cascade of signaling events (Figure 1.2) (Neufeld et al., 
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1999). However, other VEGFs can also bind to VEGFR-2 with some affinity. For 
example, VEGF-E was found to activate angiogenesis, similar to VEGF-A, after 
binding to VEGFR-2 (Meyer et al., 1999). During pathological angiogenesis, 
different types of stimuli can cause induction of VEGF-A production, and this will 
be discussed in detail below, in the context of specific neovascular disease. 
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Figure 1.2. VEGF signal transduction. Binding of VEFG-A to a VEGF receptor 
can result in multiple cellular outcomes. Blocking of heme production via terminal 
enzyme leads to decrease in activation of VEGFR-2 levels in retinal ECs. Loss of 
cellular proliferation and migration due to heme loss can be explained through 
inhibition of signaling cascade downstream of the receptor. Inhibition of heme 
synthesis leads to decrease in hemoprotein eNOS, also leading to anti-migratory 
and anti-proliferative effects in retinal ECs. 
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 Signal transduction in angiogenesis leads to downstream cues for multiple 
cellular processes like proliferation, cell survival, migration, vascular permeability, 
and ECM degradation, depending on the effectors and mediators of the pathway. 
I will highlight some pertinent intracellular signaling pathways, however it is 
important to consider that an angiogenic response is the concerted effort of 
multiple growth factors, receptors, and signaling pathways in ECs (Ucuzian et al., 
2010). Transduction of proliferation signals depend upon the activation signal 
received by the receptor. The main VEGFR-2 mediated pathway typically begins 
by extracellular binding of growth factors like VEGF-A. Phosphorylated VEGFR-2 
activates phospholipase C-γ (PLC-γ), which further cleaves phosphatidyl-inositol-
4,5-bisphosphate (PIP2) to produce diacylglycerol (DAG) and inositol-
triphosphate (IP3). DAG and IP3 can induce release of Ca2+ from the 
endoplasmic reticulum and further activate protein kinase C (PKC), and 
mediators of the extracellular signaling-regulated kinases-mitogen-activated 
protein kinases (ERK-MAPK) pathway (Cebe-Suarez et al., 2006). Activation of 
ERK-MAPK concludes with nuclear translocation and activation of transcription 
factors that mediate cellular proliferation like c-Fos, c-Myc among others (Mavria 
et al., 2006). 
 Similarly, VEGFR-2 phosphorylation can initiate signaling cascades that 
lead to transduction of cell survival signals. Phosphatidyl-inositol-3-kinase (PI3K) 
is the key effector that is recruited by activated VEGFR-2, which activates Akt 
(also known as protein kinase B). Akt can further inhibit the activity of pro-
apoptotic proteins like caspase-9, Bad, and Bax. Akt can also activate nitric oxide 
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synthase (NOS), which can cause cytoskeletal rearrangement during EC 
migration, through the action of nitric oxide (NO) on signaling proteins like focal 
adhesion kinase (FAK) (Shiojima and Walsh, 2002). The Rho family of GTP 
binding proteins like Rho, Cdc42, Rac control cytoskeletal dynamics. VEGF has 
been found primarily to be an activator of Ras-ERK-MAPK pathway. Rac and 
Cdc42 enable polymerization of actin fibers, and lamellipodia formation by 
activating p21-activated Pak. Pak can activate ERK-MAPK cascade and mediate 
cell shape and motility, required for migration. Crosstalk between effector 
proteins is commonly seen in ECs, and thus, angiogenic response is a result of a 
complex network of intracellular signaling molecules (Apte et al., 2019). 
 
1.2 Diseases of Angiogenesis 
1.2.1 Retinal and Choroidal Angiogenesis 
The retina has two major sources of vasculature for blood supply. The 
inner layers of the retina are fed by a network of retinal vessels. The retinal 
neurons consist of bipolar, horizontal, amacrine and ganglion cells, interspersed 
between the inner retinal layers and the photoreceptor cells, aiding in image 
processing (Masland, 2012). The outer retina gets its nutrient supply from the 
choroidal circulation made up by the choriocapillaris (Figure 1.3).  The 
photoreceptor cells (rods and cones) are devoid of any vessels and receive 
nutrient supply from the choroidal blood vessels. This is an important feature for 
visual processing – light is transduced by the avascular photoreceptors, without 
interference from biomolecules present in blood, to produce a clear visual image. 
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In case of a neovascular pathology, fluid and contents from blood vessels often 
leak into the sub-retinal space and thus, can impair vision. One major difference 
between the retinal vessels and choriocapillaris is the barrier function. Retinal 
ECs have tight junctions that maintain a tightly regulated blood-retina barrier, 
while the latter has no barrier function and relies on the retinal pigment 
epithelium (RPE) to maintain a blood-retinal barrier in the outer layers of the 
retina (Sun and Smith, 2018). 
Neovascularization is the process of blood vessel formation in avascular 
regions (areas devoid of any vasculature), and can involve both angiogenic and 
vasculogenic mechanisms. In the posterior section of the eye, there is scope of 
neovascularization in two areas of the vasculature – the retinal or the choroidal 
blood vessels. Neovascular vessels can be prematurely developed, due to a 
hyperproliferative state of ECs, and can leak fluid and blood in the surrounding 
subretinal space (Campochiaro, 2000). I will further elaborate on retinal and 
choroidal angiogenesis in the context of three common neovascular eye 
diseases – proliferative diabetic retinopathy (PDR), wet age-related macular 
degeneration (AMD), and retinopathy of prematurity (ROP).  
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Figure 1.3. Anatomy of the posterior section of the eye and a magnified 
illustration of the retinal layers and vasculature. NFL, nerve fiber layer; GCL, 
ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; RPE, 
retinal pigment epithelium. (Adapted from Chen J, Liu CH, Sapieha P. Retinal 
Vascular Development. In: Anti-Angiogenic Therapy in Ophthalmology, edited by 
Cham SA. New York, NY: Springer, 2016, p. 1–19.) 
 
1.2.2 Proliferative Diabetic Retinopathy (PDR) 
Diabetic Retinopathy (DR) is the leading cause of blindness in the United 
States among the working population (Fong et al., 2004). Nearly 98% of 
individuals with type-1 and 78% individuals with type-2 diabetes developed DR 
within the first 15 years of diagnosis (Varma, 2008). In the same 15 years of 
diagnosis, 33% of type-1 patients and 17% of type-2 patients develop PDR. With 
the increase in the prevalence of type-2 diabetes, this epidemiological burden 
has been projected to triple by 2050 (Saaddine et al., 2008). Central vision loss, 
 11 
blindness, maculopathy, and macular edema are some of the symptoms of PDR 
patient population (Tong et al., 2001). High levels of intravitreal VEGF, induced 
due to an ischemic retina, cause PDR. Abnormally grown neo-vessels are leaky, 
and often result in vitreous hemorrhaging, and ultimately, retinal detachment. 
PDR is the advanced form of retinal neovascularization caused due to 
hyperglycemic levels, and an imbalance between pro-angiogenic and anti-
angiogenic factors in the retina. Retinal cells fail to use insulin for glucose uptake, 
like that for other tissues, and depend on the activity of glucose transporters like 
GLUT-1 for uptake of glucose into cells (Sone et al., 2000). Hyperglycemia 
underlies the development of early stages of DR, where increased glucose levels 
lead to loss of pericytes, increase in vascular permeability, damage to blood-
retinal barrier, and formation of microaneurysms. This is followed by increased 
formation of free radicals and advanced glycation end products (AGEs), both 
leading to pronounced buildup of oxidative stress in the diabetic retina 
(Williamson et al., 1993; Stitt et al., 2005). During this stage, an intracellular 
“pseudohypoxic” environment is a common occurrence, and compounds the 
effects of increased oxidative stress, inducing the production of VEGF-A from 
retinal ECs (Aiello et al., 1994; Shinoda et al., 2000). Increased levels of VEGF-A 
in the ischemic retina further induces enhanced proliferation of ECs and results in 
retinal neovascularization (Smith et al., 1997).  
 
1.2.3 Wet Age-Related Macular Degeneration (wet AMD) 
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AMD remains the leading cause of central vision impairment in older 
adults of developed countries (Jager et al., 2008). In the United States alone, 
more than 8 million cases have been reported with intermediate AMD and 
approximately 2 million have progressed to the more advanced form of AMD 
(National Eye Institute, 2019). This number has been predicted to explode by 
2020, raising serious concerns over management of the disease. Although the 
patients with wet AMD sustain peripheral vision, the loss of central acuity 
severely burdens quality of life with an added risk of depression and visual 
hallucinations to the affected individual. Additionally, development of AMD in one 
eye also considerably increases the risk of affecting the second eye, increasing 
complications (Campochiaro, 1999).  
Early stages of AMD include accumulation of lipid and protein deposits, 
referred to as “drusen”, between the RPE and Bruch’s membrane. Drusen 
deposits in the retina is indicative as dry AMD, this can progress to geographic 
atrophy (GA), which is characterized by degeneration of the RPE and the 
photoreceptor cells. The advanced form of AMD, more commonly known as “wet” 
AMD or the exudative form of AMD is caused due to abnormal 
neovascularization in the choroidal vessels. Neovascular choroidal vessels 
invade the RPE, by rupturing the Bruch’s membrane, and release their contents 
in the outer retina and subretinal space (Campochiaro et al., 1999, Al-Zamil and 
Yassin, 2017). The exact trigger of how choroidal neovascularization is initiated 
is unclear, however several mechanisms have been postulated in the literature. 
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Multiple stressors can stimulate the production of pro-angiogenic factors 
like VEGF-A, predominantly secreted by the RPE. Drusen deposits can trigger 
inflammation and recruit components of the complement pathway like C3a and 
C5a. Oxidative stress is another stressor, known to induce CNV, and can be a 
result of genetic factors or poor lifestyle choices. Both of these stressors 
individually, or in combination, can induce RPE to secrete VEGF-A, thus initiating 
CNV. Another possible mechanism postulated is age-related thickening of the 
Bruch’s membrane, that can result in a hypoxic environment in the outer retina, 
by decreasing the supply of oxygen from the choroid to the RPE (Holz et al., 
1994). This may result in stimulation of VEGF-A production, and lead to 
angiogenesis in the choroid. It is clear that RPE is largely involved in the 
pathogenesis of AMD, and like in several aging neurodegenerative diseases, 
accumulation of damaged mitochondria in the RPE have also been reported (Lin 
and Beal, 2006).  
 
1.2.4 Retinopathy of Prematurity (ROP)  
ROP is a major cause of blindness affecting children, with nearly 16,000 
cases reported each year in the United States alone (National Eye Institute, 
2019).  Approximately 60% of preterm births develop some degree of ROP 
annually, and require medical treatment for their condition. Out of these, nearly 
35% infants lose their vision, with permanent blindness (Lad et al., 2009). ROP 
does not manifest early symptoms, while some late symptoms of ROP include 
unusual eye movements, white pupils and vision loss, often diagnosed through 
eye exam and retinal fundoscopy.  
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The pathogenesis of ROP is biphasic, with phase I being characterized by 
hyperoxia, and followed by phase II, hypoxia-driven neovascularization 
(Hellstrom et al., 2013). Preterm babies are, often, housed in a closed incubator 
with high oxygen, to improve respiration and survival. However, a detrimental 
side effect of this treatment is obliteration of the developing retinal vessels, as 
hyperoxia has been found to suppress the production of VEGF-A (Stone et al., 
1996). Subsequent transfer of neonates to normal atmospheric conditions 
creates a relative hypoxic environment in the developing retina and contributes to 
conditions conducive to abnormal neovascularization. Low birthweight, 
hyperglycemia, and low serum insulin-like growth factor, can increase the risk of 
ROP in preterm infants, and exacerbate the symptoms. Studies mimicking these 
physiological manifestations, in vitro and in animal studies, have reported 
hypoxia to be the major driver of neovascularization during phase II. The 
imbalance in oxygen concentrations in the developing retina, results in pockets of 
avascular zones, due to hyperoxia-driven obliterated vessels, and neovascular 
areas induced by hypoxia-VEGF-A-driven angiogenesis (Heidary et al., 2009).  
 
1.3 Therapy for Neovascular Eye Diseases 
Clinically, therapeutic strategies include destruction of abnormal vessels, 
restriction of abnormal vessels mediated by blockade of growth factors, and in 
some extreme cases, surgical intervention is required. Due to the common 
prevalence of VEGF-A in the underlying pathogenesis of both retinal and 
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choroidal neovascularization, anti-VEGF biologics have revolutionized 
neovascular therapy.  
In early PDR, laser photocoagulation therapy has been traditionally used, 
where laser is used to target neovessels directly in the retina. However, laser 
itself can have damaging side effects like destruction of healthy cells, retinal 
detachment, and relapse of neovascularization (Evans et al., 2014). Laser 
therapy has been proven effective in targeting peripheral vessels for ROP. 
Cryotherapy is the standard of care, used by clinicians to slow down abnormally 
growing vessels, however most severe cases of ROP remain beyond the reach 
of current treatment strategies (Cryotherapy for Retinopathy of Prematurity 
Cooperative, 2001). Intravitreal administration of anti-VEGF-A biologics are now 
included in the standard of care for wet AMD and PDR, with clinical trials 
underway for ROP. However, it is important to consider the invasive route of 
administeration of anti-VEGFs can present with complications like blurred vision, 
discomfort and/or elevated intraocular pressure. 
Humanized monoclonal antibodies like ranibizumab and bevacizumab are 
effective in binding to all isoforms of VEGF-A (Ellis, 2006; Lowe et al., 2007). 
Human recombinant protein called VEGF trap or Aflibercept consists of VEGFR 
binding domains and acts like a neutralizing antibody, capturing all VEGF-A 
isoforms (Semeraro et al., 2013). Apart from these proteins, a 28-nucleotide 
chemically synthesized RNA aptamer, called pegaptanib has also been 
approved, for its high selectivity in binding VEGF165 isoform of VEGF-A 
(Ruckman et al., 1998; Eyetech Study, 2002). Even with the success of anti-
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VEGFs, some patients still remain unresponsive to these treatments, owing to 
multifactorial pathways involved in the pathogenesis of neovascular diseases 
(Yang et al., 2016). In addition, some cases of anti-VEGF therapy show loss of 
efficacy after repeated administeration and patients are reported to develop 
tolerance to ranibizumab and bevacizumab (Keane et al., 2008;Schaal et al., 
2008) and in certain cases, these treatment regimens are limited owing to 
financial and ethical reasons. Bevacizumab was developed for treating colon 
cancer, and its use for AMD is off-label. The CATT research trial found the 
efficacy of bevacizumab equivalent to ranibizumab in improving visual acuity 
(The CATT Research Group, 2011). Additionally, FDA approved ranibizumab 
costs nearly 23,000 USD per patient annually compared to the 600 USD cost of 
administering bevacizumab (Schmucker et al., 2009; Nepomuceno et al., 2013; 
Silver, 2014).  
Thus, there is a rising need to develop novel, better therapeutic strategies, 
one that does not rely solely on the action of VEGF-A, and less invasive routes of 
administration for treatment. Detailed characterization of the mechanism of these 
pathologies is the first step towards designing different therapeutic strategies 
against these diseases. For example, without the information on growth factors 
like VEGF, anti-VEGF biologics would never have come into the picture. More 
importantly, studies on the basic cellular mechanisms in the pathogenesis of 
neovascularization, would result in better therapeutic avenues, reducing toxic 
side effects, and an improved understanding of the disease itself. 
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1.4 Heme Synthesis Proteins as Angiogenesis Mediators  
To find new angiogenesis mediators, in a reverse chemical genetics 
approach, the Corson laboratory screened an anti-angiogenic compound 
cremastranone, and identified an enzyme ferrochelatase as the cellular target 
(Basavarajappa et al., 2017). The terminal heme synthesis enzyme, 
ferrochelatase, encoded by FECH, was the first heme pathway component to be 
identified as a druggable target in pathological angiogenesis. FECH blockade 
(both genetically and pharmacologically) reduced proliferation, migration and 
endothelial tube formation in retinal and choroidal microvascular ECs. This effect 
was specific to ECs; FECH inhibition had a negligible effect on non-endothelial 
ocular cell proliferation. FECH blockade was cytostatic, with no resulting 
activation of apoptosis proteins observed in ECs. This anti-angiogenic effect was 
also seen in vivo: mice with a partial loss-of-function Fechm1Pas point mutation 
formed reduced neovascular lesions in the eye in the laser-induced choroidal 
neovascularization (L-CNV) model with features of wet AMD, as did mice with 
ocular Fech knockdown. In addition, FECH was overexpressed in and around 
these lesions, and in human wet AMD eyes (Basavarajappa et al., 2017). 
Moreover, FECH was upregulated, particularly in neovascular tufts, in the 
oxygen-induced retinopathy (OIR) mouse model of ROP (Sardar Pasha and 
Corson, 2019). FECH blockade resulted in reduced expression of angiogenesis 
signaling proteins like eNOS, VEGFR-2, activated VEGFR-2, and HIF1α. The 
mechanisms of how heme contributes to EC physiology and drives angiogenesis 
are now beginning to be understood. 
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1.5 Synthesis and Functions of Heme 
Mitochondrial function in ECs is interconnected by a mesh of signaling 
molecules that cross pathways often (Kluge et al., 2013). One such versatile 
biomolecule is heme. Heme is important for respiration, curbing oxidative stress, 
drug metabolism, and oxygen transport (Dailey and Meissner, 2013). The heme 
synthesis pathway and intermediates have been studied in detail over decades, 
with crystal structures and cloned genes available (Poulos, 2014). Intriguingly, 
heme is an important prosthetic moiety of key proteins in ECs (Chiabrando et al., 
2014b). 
In mammalian cells, heme synthesis is accomplished in the mitochondria 
and cytosol over a series of eight enzymatic reactions, followed by modification 
of heme in a couple of sub-hemylation steps (Nilsson et al., 2009; Hamza and 
Dailey, 2012; Dailey et al., 2017). Heme biosynthesis in cells other than 
erythrocytes is initiated by the rate-limiting enzyme aminolevulinic acid synthase 
(ALAS1) that catalyzes formation of 5-aminolevulinic acid (ALA) from succinyl-
CoA and glycine (Figure 1.4). ALA is exported out into the cytosol, where two 
molecules of ALA are condensed to form porphobilinogen (PBG) by 
porphobilinogen synthase (PBGS), the first pyrrole structure of the heme 
pathway. Four monopyrrole PBG are linearized to form tetrapyrrole 
hydroxymethylbilane (HMB) by HMB synthase. HMB is converted to 
uroporphyrinogen III by uroporphyrinogen synthase (UROS). The final 
cytoplasmic intermediate synthesized next is coproporphyrinogen III by 
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uroporphyrinogen decarboxylase (UROD). This coproporphyrinogen III is shuttled 
into the mitochondrial intermembrane space, where coproporphyrinogen oxidase 
(CPOX) produces protoporphyrinogen IX. The second last step is catalyzed by 
protoporphyrinogen IX oxidase to produce protoporphyrin IX (PPIX). In the final 
step, ferrochelatase (FECH) incorporates ferrous iron into protoporphyrin IX 
(PPIX), synthesizing protoheme. Heme is then available to enable cellular 
processes by combining with enzyme subunits as a prosthetic group. For 
example, heme-iron is part of the catalytically active form of eNOS (Raman et al., 
1998). Similarly, different forms of heme are incorporated into mitochondrial 
respiratory complexes II-IV of the electron transport chain (ETC) (Kim et al., 
2012). Of course, the majority of heme is used for incorporation into hemoglobin 
during erythropoiesis (Korolnek and Hamza, 2014) and some (primarily in the 
liver) for the synthesis of cytochrome P450s, responsible for xenobiotic 
metabolism (Correia et al., 2011).  
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Figure 1.4. Schematic diagram of the heme synthesis pathway in the 
mitochondrion. Eight sequential steps in the heme synthesis pathway are 
depicted, along with some heme-containing proteins. Red dotted lines indicate 
blockade. Succ CoA, succinyl-CoA, ALA, 5-aminolevulinic acid; ALAS, ALA 
synthase; ALAD, ALA dehydratase; HMBS, hydroxymethylbilane synthase; 
UROS, uroporphyrinogen synthase; UROD, uroporphyrinogen decarboxylase; 
CPOX, coproporphyrinogen oxidase; PPOX, protoporphyrinogen oxidase; FECH, 
ferrochelatase; PPIX, protoporphyrin IX; eNOS, endothelial nitric oxide synthase; 
CYP450, cytochrome P450; ETC, electron transport chain. 
 
Apart from being a prosthetic cofactor for enzymes, heme’s regulated 
production ensures that active iron is sequestered before it can promote 
formation of reactive oxygen species (ROS) (Ryter and Tyrrell, 2000). Hence, 
heme plays a crucial role in ROS homeostasis in the mitochondria, without which 
many mitochondrial processes would be damaged (Alonso et al., 2003). One key 
 21 
regulator involved in detoxification of ROS and stimulating mitochondrial 
biogenesis is proliferator-activated receptor gamma coactivator 1α (PGC1α) 
(Austin and St-Pierre, 2012). PGC1α regulates ALAS1 expression in the liver, 
linking heme synthesis directly to the nutritional state of cells (Handschin et al., 
2005). Fasting-induced PGC1α was found to be essential for vascular growth 
and pathological angiogenesis (Saint-Geniez et al., 2013). In the following 
sections, I will review recent studies that have identified an unexpected link 
between angiogenesis and heme synthesis, offering exciting therapeutic 
relevance to neovascular diseases like PDR, wet AMD and ROP discussed 
previously. 
 
1.6 Mechanisms of Heme Regulation of Angiogenesis 
1.6.1 Mitochondrial Function 
Inhibition of heme synthesis has varying impact on the hemoproteins 
(heme-binding proteins) of the ETC (Vijayasarathy et al., 1999; Atamna et al., 
2001). Heme b and c are present in complexes II and III, whereas complex IV 
has two groups of heme a, made after two consecutive modifications to 
protoheme (Kim et al., 2012). Heme biosynthesis inhibition in vivo was found to 
decrease expression of key mitochondrial subunit proteins of complex IV like 
COX1, COX2 and COX5 in liver, brain and kidney tissues (Vijayasarathy et al., 
1999). Chemical inhibition of FECH showed similar effects on complex IV in other 
cell types like IMR90 fibroblast, neuroblastoma and astrocyte cells (Atamna et 
al., 2001; Atamna et al., 2002). There is increasing evidence of the involvement 
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of COX and mitochondrial reactive oxygen species (ROS) activity in VEGF 
induced pro-angiogenic stimuli in umbilical vein ECs (Wang et al., 2011). COX 
muscle-specific knockout exhibits reduced capillaries in skeletal muscle, 
indicating an important role for complex IV in angiogenesis (Lee et al., 2012). 
However, the direct effect on ETC activity after heme depletion in the retina has 
not been studied before. 
 
1.6.2 Cytosolic Effects 
Lack of heme synthesis also leads to incomplete formation of eNOS and 
reduced activity (Feng, 2012). Heme depletion via FECH inhibition led to 
decreased expression, hemylation, and activity of eNOS in retinal microvascular 
ECs (Basavarajappa et al., 2017). Heme inhibition by chemically blocking the 
second synthesis enzyme aminolevulinic acid dehydratase (ALAD) in rats led to 
reduced eNOS and downstream mediator soluble guanylyl cyclase (sGC), both 
important in maintaining regular cardiovascular function. These effects did not 
affect vascular tension and resulted in no change to arterial blood pressure 
(Bourque et al., 2010). But heme depletion-driven eNOS dysfunction led to 
impaired NO mediated vascular relaxation in bovine coronary arteries (Zhang et 
al., 2018). NO, a potent vasodilator, is pro-angiogenic and NO itself is known to 
inhibit hemylation of extramitochondrial apo-hemoproteins (Waheed et al., 2010). 
Heme oxygenase-1 (HO-1) is a heme degradation enzyme and a stress protein 
induced by hypoxic conditions which causes release of NO in ECs (Motterlini et 
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al., 2000). HO-1 inhibition by tin protoporphyrin-IX (SnPPIX) reduced VEGF-
induced angiogenesis in ECs (Jozkowicz et al., 2003). 
It is important to note that heme overload in ECs also leads to abnormal 
angiogenesis. Silencing of the heme transporter FLVCR1a led to intracellular 
heme accumulation in microvascular ECs, but not in macrovascular ECs. This 
heme accumulation in microvascular ECs led to impaired angiogenesis, 
damaged vessel formation and embryonic lethality in vivo (Petrillo et al., 2018). 
Heme toxicity has been investigated previously in hemolytic diseases like sickle 
cell disease and thalassemia, where heme scavengers are helpful in reducing 
heme-induced ROS accumulation (Vinchi et al., 2013). In non-small cell lung 
cancer, tumor cells had elevated heme synthesis activity, increasing respiratory 
function of the ETC and enhancing tumorigenic properties like migration and 
invasiveness (Sohoni et al., 2019). This suggests in addition to heme loss being 
anti-angiogenic, heme synthesis overdrive can increase mitochondrial function, 
but this remains to be validated in ECs. 
 
1.7 Summary, Hypothesis, and Aims 
Angiogenesis is a double-edged sword that can work both therapeutically 
for some diseases as well as being damaging in others. Abnormal angiogenesis 
underlies many pathologies like neovascular eye diseases, tumors, and 
inflammatory diseases whereas angiogenesis is favorable for revascularization in 
case of stroke, myocardial infarction, neurodegeneration and ischemia (Chung 
and Ferrara, 2011). ECs that line newly sprouting vasculature drive the process 
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of angiogenesis. ECs of microvascular origin are predominant in these 
neovessels (Jackson and Nguyen, 1997). VEGF-driven angiogenesis signal 
transduction is considered a common downstream pathway. 
We previously demonstrated that inhibition of FECH was sufficient to block 
angiogenic function of these microvascular ECs (Basavarajappa et al., 2017). 
FECH overexpression is seen in human patient samples of wet AMD as well as 
in an animal model of neovascularization. Inhibition of FECH reduces 
neovascularization in vivo without toxicity. Loss of FECH directly affects heme 
biosynthesis by reducing heme production and causes accumulation of precursor 
PPIX levels. Depletion of heme will eventually affect heme containing proteins 
and hemoprotein-regulated pathways, for example proteins of the ETC, which will 
be discussed in subsequent chapters in this thesis. However, the detailed 
function of FECH in angiogenesis has not been described previously. I 
hypothesized that FECH is a mediator of pathological angiogenesis via 
altering mitochondrial function of endothelial cells. To test my central 
hypothesis, I proposed the following aims – 
Aim I: Determine the bioenergetic profile of retinal and choroidal ECs. 
To address this aim, I determined optimized parameters essential for determining 
basal energetics of retinal and choroidal ECs. I determined optimal cell seeding 
density that provides maximal oxygen consumption rates and extracellular 
acidification rates. I distinguished ATP production from mitochondrial respiration 
and glycolysis and recorded basal and stressed energy outputs. These studies 
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characterized the physiologic energetic state of ECs and helped in designing 
experiments under FECH inhibition conditions.  
Aim II: Elucidate mitochondrial function of ECs under FECH blockade. 
I addressed this by examining mitochondrial parameters like morphology, mass, 
dynamics, membrane potential and oxidative stress after FECH inhibition. I 
studied the cellular bioenergetics of retinal and choroidal ECs and retina in vivo 
after FECH inhibition, using Seahorse extracellular flux measurements. 
Expression, function and activity of complexes of the ETC was examined under 
conditions of FECH blockade. These experiments identified the role of FECH and 
thus, heme synthesis in maintaining mitochondrial function of ECs. 
Aim III Characterize the retinal phenotype of partial loss-of-function Fech 
mutation in vivo. 
Here, I characterized the retinal structural and physiological phenotype after loss 
of Fech activity in a mouse model of Fech partial loss-of-function mutation 
(Fechm1Pas). I documented retinal fundus appearance, vessel integrity and PPIX 
levels in Fechm1Pas mice of wild-type (WT), heterozygous and homozygous 
genotypes. To assess retinal function, I recorded visual activity using 
electroretinography. I characterized the retinal bioenergetic function using 
Seahorse extracellular flux analyzer. To determine aberrations in developing as 
well as fully developed pre-existing retinal vessels, I assessed retinas from 
juvenile and adult Fechm1Pas mice. These experiments provided the first study of 
retinal physiology of the Fechm1Pas mouse model and together, my results 
provided a comprehensive study of heme deficiency in the eye.  
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1.8 Dissertation Overview 
 This dissertation will describe experiments performed towards testing the 
above-mentioned hypothesis by addressing the specific aims outlined in this 
chapter. Chapter II will detail the materials and methods used in designing the 
experiments in subsequent chapters. Chapter III will cover experiments 
addressing Aim I and will provide optimized parameters for using the Seahorse 
extracellular flux analyzer, which will be used in Chapters IV and V for studying 
bioenergetics of ECs and retina. The Seahorse technology will be detailed in this 
chapter, with the importance and limitations of its use in vitro and in vivo. Chapter 
IV will address Aim II and provide results for mitochondrial function of ECs after 
FECH loss. This chapter will outline findings in vitro in retinal and choroidal ECs, 
and go on to document the effect seen in vivo after FECH inhibition. In order to 
understand retinal physiology under an inherent point mutation in Fech in vivo, 
Chapter V will elaborate on results from retinal characterization of Fechm1Pas 
mouse model, specified in Aim III. Together, all results will be discussed in 
Chapter VI, while addressing limitations and potential future studies that can be 
explored as an outcome of this dissertation project. 
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CHAPTER 2. METHODOLOGY 
2.1 In Vitro Experiments 
2.1.1 Cell Culture 
HRECs and Attachment Factor were purchased from Cell Systems 
(Kirkland, WA, USA). HRECs were grown in endothelial growth medium  
(EGM-2) and used between passages 4 and 8. EGM-2 was prepared by 
combining components of EGM-2 “bullet kit” (Cat no. CC-4176) and endothelial 
basal medium (EBM, Lonza, Walkersville, MD, USA; Cat No. CC-3156). RF/6A 
cells were obtained from ATCC (Manassas, VA, USA) and grown in Eagle’s 
Minimum Essential Medium (EMEM, ATCC Cat No. 30-2003) supplemented  
with 10% fetal bovine serum (FBS, PAA Laboratories, Etobicoke, ON, Canada; 
Cat No. A15-751). Since short tandem repeat profiles are not available for 
Rhesus, these cells were not authenticated after receipt from the supplier, and 
sex was not reported. Glucose, sodium pyruvate and L-glutamine were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). XF Base Dulbecco’s 
Minimum Essential Medium (Cat No. 102353-100) and XFp FluxPak (Cat No. 
103022-100) were purchased from Seahorse Biosciences (Billerica, MA, USA). 
Cells were reordered from the suppliers at least annually, and grown at 37°C in  
a 5% CO2 incubator. Cultures were routinely tested for mycoplasma 
contamination. N-methyl protoporphyrin (NMPP) was purchased from Frontier 
Scientific (Logan, Utah, USA) and prepared in DMSO. HRECs were treated with 
10 µM and RF/6A at 100 µM NMPP for 48 hours. FECH siRNA 
(SASI_Hs01_00052189 and SASI_Hs01_00052190) was purchased from Sigma 
and MISSION® siRNA Universal from Sigma was used as a negative siRNA 
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control. HRECs were transfected with 30 pmol of either control or FECH siRNA 
for 48 hours using 7.5 µl of Lipofectamine RNAiMAX reagent (Life  
Technologies).  
 
2.1.2 FCCP Titration and Cell Seeding Density 
OCR was measured using the Seahorse Extracellular XFp Analyzer 
(Agilent, Santa Clara, CA, USA) at the Indiana University School of Medicine 
Angio BioCore. The Seahorse XFp Analyzer makes use of sensor probes that 
measure changes in oxygen and pH, to assess energy consumption from a 
monolayer of cells, in real time. The sensor probes contain embedded 
fluorophores that measures changes in O2 and H+ in the cellular 
microenvironment, in response to specific mitochondrial inhibitors (for example 
FCCP, oligomycin etc.), injected transiently into the microplate containing cells.  
This method allows determination of a kinetic measurement of oxygen 
consumption directly correlating with oxidative phosphorylation by the ETC, 
indicating mitochondrial function of ECs.  
Cells (2104 per well) were seeded overnight in XFp miniplates. Sensor 
cartridges were hydrated overnight in XF calibrant in a room air incubator. Next 
day, XF Base assay medium was prepared by addition of 5.5 mM glucose and 
0.61 mM sodium pyruvate. For HRECs, 3.2 mM L-glutamine was used, while for 
RF/6A cells 1.6 mM concentration was used as per their respective routine 
culture medium compositions. The unbuffered base medium was filter sterilized 
followed by pH adjustment to 7.4 using 0.2 N NaOH solution. Cells were rinsed 
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with base medium twice to remove overnight culture medium and this was 
replaced with base assay medium. Cells were incubated for a minimum of 1 hour 
in a room air incubator before proceeding with the assay. For determining optimal 
FCCP concentration, two ranges of FCCP were used. Low range concentrations 
of 0.125, 0.25 and 0.5 µM and high range concentrations of 0.5, 1 and 2 µM were 
used for titration. Cells were first treated with oligomycin at 1 µM concentration 
followed by three serial injections of FCCP low and high range concentrations. 
For the cell seeding density experiment, cells at 5103, 2104 and 4104 cells per 
well were plated overnight, photographed using an EVOS fl digital microscope, 
and then subjected to OCR and ECAR measurements to determine optimal cell 
number for assay conditions. 
 
2.1.3 Cell Energy Phenotype 
Cells were grown, as indicated, overnight followed by assessment of metabolic 
phenotype using the Seahorse XFp Cell Energy Phenotype test kit (Cat. No. 
103275-100). Stressor mix was prepared by combining 1 µM oligomycin and 
0.125 or 1 µM FCCP. Cells were incubated in base medium for 1 hour in a room 
air incubator prior to measurements. Five cycles of readings were taken after the 
injection of stressor mix on the cells and kinetic traces indicating OCR and ECAR 
were produced in tandem. 
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2.1.4 Mitochondrial Energetics 
For measuring mitochondrial function, Seahorse XFp Cell Mito Stress test 
kit (Cat No. 103010-100) was used (Dranka et al., 2011). Mitochondrial inhibitors 
at final well concentrations of 1 µM oligomycin, 0.125 µM (for RF/6A cells) or 1 
µM FCCP (for HRECs) and 0.5 µM rotenone/antimycin A were prepared using 
freshly buffered base medium. After incubating cells in a room air incubator, 
oxygen consumption rate (OCR) readings were determined using the XFp 
analyzer. The assay program was set up to measure three cycles of oligomycin 
followed by FCCP and a final injection of rotenone/antimycin A.  
 
2.1.5 Glycolytic Function 
Glycolytic parameters were measured using the Seahorse XF Glycolysis 
Stress test kit (Cat No. 103020-100). Cells (2104 per well) were grown overnight 
followed by glucose starvation in assay medium containing sodium pyruvate and 
glutamine for 1 hour in a room air incubator. Compounds modulating glycolysis 
were prepared using the same assay medium. Glucose at a final well 
concentration of 10 mM, oligomycin at 1 µM and 2-deoxyglucose at 50 mM were 
loaded onto ports of the hydrated sensor cartridge followed by measurement of 
extracellular acidification rate (ECAR) using the XFp analyzer. 
 
2.1.6 ATP Production Rate Assay 
Cells (2104 per well) were seeded and grown overnight in a miniplate 
followed by replacement of culture medium with Seahorse XF DMEM Medium  
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pH 7.4 supplemented with glucose, pyruvate and glutamine and incubation in a 
room air incubator for an hour. Working stocks of oligomycin and antimycin 
A/rotenone mixture were prepared fresh prior to assay and loaded into sensor 
cartridges at 1.5 µM and 0.5 µM final well concentrations respectively. The  
assay was run using the XFp analyzer according to the manufacturer’s 
instructions and kinetic traces for OCR and ECAR were generated. 
 
2.1.7 mRNA Quantification Using qPCR 
RNA was isolated using Trizol reagent, 1 µg RNA was used for cDNA 
synthesis, made using iScript cDNA synthesis kit from Bio Rad (Cat no.  
1708897, Hercules, CA, USA). TaqMan probes for MFN2 (Hs00208382_m1), 
DNM1L (Hs01552605_m1), OPA1 (Hs01047013_m1), and FECH 
(Hs01555261_m1) were purchased from Thermo Fisher Scientific (Pittsburgh, 
PA, USA). qPCR was performed using Fast Advanced Master Mix, TaqMan 
probes, and a ViiA7 thermal cycler (Applied Biosystems). Gene expression was 
determined using ΔΔCt method and HPRT (Hs02800695_m1) as housekeeping 
control and normalized to individual sample controls. 
 
2.1.8 Immunoblotting 
Cells were lysed in RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA, Cat 
no. R0278) and processed for protein quantification followed by SDS-PAGE. For 
ETC proteins, total OXPHOS Rodent WB Antibody Cocktail (Abcam, ab110413, 
Cambridge, MA, USA) at 1:250 dilution was used. COX IV-1 antibody was 
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purchased from Thermo Fisher Scientific (Cat no. PA5-19471, Pittsburgh, PA, 
USA) and used at 1:1000 dilution. -actin antibody was purchased from Sigma 
(Cat no. A5441) and used at 1:2000 dilution. FECH antibody was purchased  
from LifeSpan BioSciences (Seattle, WA, USA, Cat no LS C409953) and used  
at 1:500 dilution prepared in 5% BSA solution. Chemiluminescent reagent ECL 
Prime was purchased from GE Healthcare (Buckinghamshire, UK, Cat no. 
RPN2232). 
 
2.1.9 Protoporphyrin IX Quantification 
PPIX analysis was performed at the Iron and Heme Core facility at the 
University of Utah. Briefly, cells were washed with PBS, pelleted, and stored 
frozen at -80°C. The cells were homogenized and extraction solvent 
(EtOAc:HOAc, 4:1) was slowly added to 50 µL concentration-adjusted sample 
and shaken. The mixture was centrifuged, supernatant was collected and the 
supernatant solution was injected into a Waters Acquity ultra performance liquid 
chromatography (UPLC) system with an Acquity UPLC BEH C18, 1.7 µm, 2.1 x 
100 mm column. PPIX was detected at 404 nm excitation and 630 nm emission. 
Solvent A was 0.2% aqueous formic acid while Solvent B was 0.2% formic acid 
in methanol. The flow rate was kept at 0.40 mL per minute and the column 
maintained at 60˚C for the total run time of 7 min. The following successive  
linear gradient settings for run time in minutes versus Solvent A were as follows: 
0.0, 80%; 2.5, 1%; 4.5, 1%; 5.0, 80%. 
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2.1.10 Mitochondrial Morphology 
Cells were plated on 35 mm coverslip bottom dishes. HRECs were  
stained using MitoTracker Green (Thermo Fisher, Cat no M7514) at 200 nM for 
10 minutes in the dark at 37°C. Imaging was performed immediately following 
staining using an LSM700 confocal microscope (Zeiss, Thornwood, NY, USA) 
under a 63× oil immersion lens and acquired Z-stacked images were analyzed 
using ImageJ software (Trudeau et al., 2010). Briefly, individual cells were 
selected and particle analysis was performed to determine form factor 
(perimeter2/4π*area) and aspect ratio (length of major and minor axes). 
Mitochondria of 12 cells per condition were analyzed and the mean per cell was 
considered for further statistical tests. 
 
2.1.11 Mitochondrial Membrane Potential Assessment 
Membrane potential (ΔΨm) was measured with 5,5′,6,6′-tetrachloro-
1,1′,3,3′-tetraethylbenzimidazolcarbo cyanine iodide (JC-1) (Santa Cruz, Santa 
Cruz, CA, USA) dye (Perelman et al., 2012). JC-1 is a polychromatic cationic  
dye that on excitation accumulates in the membrane bound mitochondria as red 
aggregates and green monomers depending on the energized or deenergized 
state of the mitochondria. High mitochondrial membrane potential (or negative 
interior potential of mitochondria compared to cytosol) leads to accumulation of 
high concentrations of JC-1 aggregates that emit red fluorescence.  In case of 
low interior potential, JC-1 dye forms monomers that fluoresce green.  Cells were 
stained with JC-1 dye at 5 µg/mL final concentration for 10 minutes in the dark at 
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37°C. Cells were washed with 1× HBSS and prepared for flow cytometry 
(FACSCalibur, BD Biosciences, San Jose, CA) in Fluorobrite DMEM. JC-1 dye 
after accumulation in mitochondria forms red aggregates and green monomers 
that emit fluorescence at 590 nm and 510 nm respectively. For live imaging, cells 
grown in coverslip bottom 35mm dishes were stained and imaged using the 
Zeiss confocal microscope under a 63× oil immersion objective. 
 
2.1.12 Mitochondrial ROS Measurement 
Cells were labeled with MitoSox ROS (Thermo Fisher Scientific) dye at 5 
µM final concentration for 10 minutes in the dark at 37°C using phenol red-free 
Fluorobrite DMEM. Cells were washed and stained with Hoechst 33342 stain for 
10 minutes at room temperature. Flow cytometric analysis was performed at 
Indiana Center for Biomedical Innovation. For flow cytometry, cells were labeled 
with dye at 1 µM final concentration, incubated in the dark at 37°C and 
immediately loaded for ROS fluorescence detection in the FL-2 channel using BD 
FACSCalibur flow cytometer (Kauffman et al., 2016).  
 
2.1.13 Complex IV Activity 
ELISA was performed on cell lysates treated using COX IV ELISA kit 
(Abcam, Cambridge, MA, USA, Cat no. ab109909) following manufacturer’s 
instructions. Briefly, 10 µg protein was loaded into plates coated with COX IV 
antibody and cytochrome c reduction by the immunocaptured COX IV from the 
sample was measured, using absorbance at 550 nm. Kinetic reads were 
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obtained and slopes directly correlating to enzyme activity were determined. 
Total amount of COX IV was also assessed on the same samples. 
 
2.1.14 Hemin Rescue 
For hemin rescue experiments, hemin (Sigma-Aldrich, Cat no H9039) 10 
µM (final well concentration) was freshly prepared in DMSO. Cells pretreated 
with NMPP were supplemented with hemin in EBM2 containing 0.2% FBS for 6 
hrs, followed by harvesting and processing for immunoblotting or ELISA. 
 
2.2 In Vivo Experiments 
2.2.1 Animals 
Animal studies were approved by the Indiana University School of 
Medicine Institutional Animal Care and Use Committee, and were consistent with 
the Association for Research in Vision and Ophthalmology Statement for the Use 
of Animals in Ophthalmic and Visual Research. C57BL/6J wild-type, healthy 
female mice, 8 weeks of age were purchased from Jackson Laboratories and 
group housed under standard conditions (Wenzel et al., 2015). For technical 
ease of housing conditions, males were excluded from this study. NMPP at 10 
µM final vitreous concentration was injected intravitreally into naïve mice under 
ketamine/xylazine anesthesia as described (Sulaiman et al., 2016), and 24 hrs 
post-injection, animals were euthanized, and retinas were immediately isolated 
from the animals and processed for the energetics experiment. 
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2.2.2 PPIX Fundus Imaging 
Mice were anesthetized and eyes were topically administered with 1% 
tropicamide solution and hypromellose ophthalmic demulcent solution (Gonak, 
Akorn, Lake Forest, IL). PPIX fluorescence (excitation at 403 nm, emission at 
628 nm) was measured under a bandpass filter using the Micron IV system 
(Phoenix Research Labs, Pleasanton, CA). Fundus images were captured for 
each individual eye and images were further processed for qualitative analysis. 
 
2.2.3 Retinal Vasculature Staining 
Eyes were harvested from postnatal day 3 and 2-month old adult mice. 
Individual retina was dissected from the posterior chamber of the eye and fixed in 
4% paraformaldehyde overnight at 4°C. The following day, retina was washed 
with 1X PBS, permeabilized in blocking buffer containing 0.5% Triton X-100 in 
5% BSA solution for 2 hours at room temperature and incubated in GS-IB4 
isolectin (Biotin, 1:250 dilution, Invitrogen, Cat no., 121414) for 48 hours under 
static conditions at 4°C. Retinal flatmounts were then incubated in secondary 
antibody overnight at 4°C. This was followed by mounting retinal tissues on glass 
slides using Fluoromount-G (Southern Biotech, Birmingham, AL) and imaged 
using confocal microscopy. 
 
2.2.4 Retinal Structure and Integrity Using Optical Coherence Tomography 
and Histological Sections 
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Retinal layers were assessed by optical coherence tomography (OCT) 
imaging, using rodent Micron IV system (Phoenix Research Labs, Pleasanton, 
CA). Mice were anesthetized by intraperitoneal injections of 80 mg/kg ketamine 
hydrochloride and 10 mg/kg xylazine. Eyes were dilated with 1% tropicamide 
solution and lubricated with hypromellose ophthalmic demulcent solution (Gonak, 
Akorn, Lake Forest, IL). Mice were placed on a heated stage and the anterior 
part of the eye was positioned appropriately for acquiring OCT images.  
For examining histological sections of the posterior section of individual 
eyes, mice were euthanized and eyes were enucleated for overnight fixation in 
4% paraformaldehyde solution. Eyes were processed embedded in paraffin and 
sectioned at 5 µM thickness by the Indiana University School of Medicine 
Histology Core. Hematoxylin and eosin staining was performed, and retinal 
structure and morphology was assessed. The thickness of retinal layers was 
determined by calculating the distance between ganglion cell layer to inner 
nuclear layer and to outer nuclear layer and by counting DAPI stained nuclei in 
the three respective nuclear layers (Park et al., 2014).  
 
2.2.5 Retinal Mitochondrial Bioenergetics 
For retinal ex vivo OCR measurements, protocols were adapted as 
previously described (Joyal et al., 2016; Kooragayala et al., 2015). Briefly, eyes 
were enucleated and retina was isolated from the posterior cup. Retinal punches 
(1 mm diameter) were dissected from an area adjacent to optic nerve to minimize 
variability in retinal thickness. Retinal punches were incubated in Seahorse XF 
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DMEM Medium pH 7.4 containing 5 mM HEPES supplemented with 12 mM 
glucose and 2 mM L-glutamine for 1 hour in a room air incubator at 37°C. For 
OCR measurement, 0.5 µM FCCP and 0.5 µM rotenone/antimycin A were 
injected and OCR readings were determined. 
 
2.2.6 Electroretinogram for Assessing Visual Activity 
Mice were anesthetized by intraperitoneal injections of 80 mg/kg ketamine 
hydrochloride and 10 mg/kg xylazine. Eyes were dilated with 1% tropicamide 
solution and lubricated with hypromellose ophthalmic demulcent solution (Gonak, 
Akorn, Lake Forest, IL). Electroretinogram (ERG) was measured using an 
electrodiagnostic LKC system (UTAS-E 2000, LKC Technologies, Gaithersburg, 
MD) to assess the function of the retina. Mice were dark adapted overnight 
before taking measurements for scotopic a-wave and b-wave responses 
(Benchorin et al., 2017).  Scotopic rod measurements were recorded following 
white light flashes of increasing intensities of 0.025, 0.25 and 2.5 log cd･s/m2, at 
time intervals of 10, 20 and 30 seconds. For measurement of photopic cone 
responses, mice were light adapted to a white background for 10 minutes, 
followed by flashes of light stimulation at 0, 5, 10 and 25 log cd･s/m2 intensities. 
The trace amplitude between time 0 and the lowest point on the trace was 
considered as a-wave and the amplitude between the lowest trace and the 
highest peak following oscillatory potentials, was considered as b-wave.  
 
2.3 Software and Statistical Analysis 
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All Seahorse kinetic traces were analyzed using Wave 2.4 software 
(Agilent) and GraphPad Prism v. 8.0. FCS files for flow cytometry were analyzed 
using FlowJo v10. Image quantification for mitochondrial morphology and 
immunoblotting was done using ImageJ v1.52. Comparisons between groups 
were performed using GraphPad Prism v8 with either unpaired, two-tailed 
Student’s t-test or one-way ANOVA with Tukey’s post-hoc tests as indicated. p 
values < 0.05 were considered statistically significant. Mean±SEM shown for all 
graphs unless indicated otherwise; n is listed in figure legends. 
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CHAPTER 3. ASSESSMENT OF CELLULAR BIOENERGETICS OF 
OCULAR ENDOTHELIAL CELLS 
3.1 Summary 
Metabolic dysfunction in endothelial cells underlies many ocular diseases 
characterized by pathological angiogenesis. Here, I sought to determine the 
metabolic phenotype of HRECs and RF/6A cell line by measuring changes in 
their oxygen consumption rate and extracellular acidification rate due to various 
stressor cues. I aimed to develop a standardized protocol for assessment of 
these parameters in these widely used ocular cell models. I used a Seahorse 
extracellular flux analyzer to measure changes in O2 and pH after injecting 
inhibitors of the electron transport chain and glycolysis. I also measured ATP 
production rate to distinguish between pathway specific sources of cellular 
energy. I determined optimized cell seeding density and doses of potential-
gradient uncoupler, and measured oxygen consumption as well as acidification 
rate of the medium. 
Under these optimized assay conditions, I observed a difference in energy 
phenotype as well as ATP production between these two cell types, with HRECs 
relying on oxidative phosphorylation to meet energy needs and RF/6A preferring 
glycolysis under stress. I also determined oxidative phosphorylation and 
glycolysis parameters essential for their cellular metabolism. Knowledge of the 
baseline bioenergetic phenotype of ocular endothelial cells will be crucial for 
studying defects in complexes of the electron transport chain as well as 
dysregulated glycolysis behavior in different disease models. 
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3.2 Background and Rationale 
 Mitochondrial function is responsible for maintaining important cellular 
processes like oxidative phosphorylation, programmed cell death, oxidative 
stress, heme biosynthesis, mitophagy and calcium signaling (Kluge et al., 2013; 
Tang et al., 2014). These basic functions work in consortium, and damage to 
these mitochondrial dynamics can cause endothelial dysfunction and 
development of vascular diseases. As detailed in Chapter 1, such diseases of the 
posterior eye vasculature include ROP, PDR and wet AMD, are all characterized 
by neovascularization, driven by either retinal or choroidal microvascular ECs 
(Bharadwaj et al., 2013).  
Mitochondrial dysfunction is associated with many retinal diseases (Barot 
et al., 2011; Lefevere et al., 2017). Formation of DNA base mismatches and 
mitochondrial DNA damage have been implicated in the pathobiology of diabetic 
retinopathy (Mishra and Kowluru, 2018). Post-translational modifications of 
mitochondrial transcription factors can impair biogenesis of mitochondria (Santos 
et al., 2014). Relevant to PDR, high glucose has been shown to disrupt 
mitochondrial morphology, membrane potential and respiratory functions in rat 
retinal endothelial cells and bovine retinal pericytes (Trudeau et al., 2011; Tien et 
al., 2017). High glucose also triggered increased mitochondrial DNA methylation 
(Mishra and Kowluru, 2015), mitochondrial DNA damage, increased reactive 
oxygen species levels and reduced mitochondrial membrane potential (Xie et al., 
2008). Tigecycline, an FDA approved antibiotic, was recently shown to reduce 
mitochondrial respiration in Y79 retinoblastoma cells and HRECs and was 
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effective in suppressing retinoblastoma and angiogenesis pre-clinically (Xiong et 
al., 2018). Anti-VEGF agents like aflibercept used clinically for anti-angiogenic 
therapy provide a protective function to RPE by restoring mitochondrial 
membrane potential (De Cilla et al., 2017), indicating the importance of 
mitochondrial function directly in therapy.  
Given the significance of mitochondrial function in the mechanisms of 
retinal diseases, understanding the bioenergetic profile of posterior eye 
microvascular ECs is crucial. However, this profile remains undocumented for the 
primate endothelial cell line RF/6A, established from rhesus retina-choroid tissue 
(Lou and Hu, 1987) and widely used as a model of choroidal endothelial cells 
(Rusovici et al., 2013; Cabrera et al., 2016; Basavarajappa et al., 2017). 
Moreover, the bioenergetic profile has not been explored in detail in primary 
human retinal microvascular endothelial cells (HRECs), another widely-used in 
vitro angiogenesis model (Liu et al., 2017; Xiong et al., 2018).  
Before we can understand the role of mitochondrial deregulation in cellular 
disease models, the metabolic characteristics of mitochondria in these cells 
under normal conditions need to be established. In this chapter, I aimed to 
characterize the cellular bioenergetics of these ocular endothelial cells from the 
retina and choroid. I investigated the basal energy phenotype of HREC and 
RF/6A cells and measured their ability to meet energy demands under metabolic 
stress. I used the Seahorse extracellular flux (XF) analyzer, which detects 
changes in O2 and protons from cells in real time by making use of fluorescent 
sensors (Divakaruni et al., 2014). This system has been used previously for 
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assessing metabolism of other ocular cell types, including Müller glial cells (Tien 
et al., 2017), retinoblastoma (Xiong et al., 2018), pericytes (Trudeau et al., 2011), 
RPE (Iacovelli et al., 2016; Kurihara et al., 2016), and even whole retina 
(Kooragayala et al., 2015), however, not in microvascular ECs. 
The results in this chapter provide optimal key parameters ideal for these 
assays in ocular endothelial cells. Mitochondrial stress was induced using a 
serial injection of inhibitors oligomycin, carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP), rotenone, and antimycin A. 
Oligomycin inhibits ATP synthase allowing measurement of ATP related to 
mitochondrial respiration, while FCCP is an ETC uncoupler. Antimycin A and 
rotenone, complex I and III inhibitors respectively, shut down ETC function to 
reveal oxygen consumption rate (OCR) from non-mitochondrial sources. I also 
measured the extracellular acidification rate (ECAR) of cells by inducing stress 
by brief glucose starvation. This was followed by stimulation of glycolysis with a 
saturating dose of glucose and blockade of mitochondrial ATP production by 
oligomycin. I confirmed glycolytic function using deoxyglucose (2-DG) and 
measured glycolytic capacity. 2-DG competitively binds to hexokinase, blocking 
the glycolysis pathway and revealing ECAR unrelated to glycolysis. Finally, in 
this chapter, I also report, for the first time in endothelial cells, a real-time ATP 
production rate assay that allows ATP measurement from both mitochondrial 
respiration and glycolysis. 
 
  
 44 
3.3 Results 
3.3.1 Optimization of Uncoupler FCCP Concentration Produces Maximal 
Respiration at 1 µm and 0.125 µm Concentrations 
Uncoupler FCCP induces uninhibited flow of electrons across the ETC, 
causing the enzymes of the respiratory chain to use metabolic substrates at full 
potential and in turn, revealing the maximal cellular capacity that can meet 
energy demands under metabolically stressed conditions. To determine the 
FCCP dose that produces the highest maximal respiration, I chose to perform 
titrations of increasing concentrations of FCCP. Cells were injected with 
concentrations of FCCP ranging from 0.125 µM to 2 µM and their maximal OCR 
was measured. HRECs produced maximal respiration at 1 µM FCCP 
concentration (Figure 3.1A). RF/6A needed 0.125 µM FCCP to produce   
maximal respiration (Figure 3.1B). I proceeded to use these FCCP 
concentrations for all experiments in this thesis, in order to compare the FCCP-
induced maximal respiration to the respective cell type’s basal respiration 
parameter.  
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Figure 3.1. Optimization of uncoupler FCCP concentration that produces 
maximal respiration in ocular endothelial cells. Oxygen consumption rate (OCR) 
traces of (A) HRECs and (B) RF/6A cells. 2104 cells seeded. Mean ± SEM, n=3. 
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3.3.2 Cellular Energetic Behavior of HRECs and RF/6A Differ Under 
Metabolic Stress 
 To determine the energy phenotype of HRECs and RF/6A cells, I tested 
ATP synthase inhibitor oligomycin and mitochondrial uncoupler FCCP. Induced 
stress caused HRECs to use both oxidative phosphorylation as well as  
glycolysis to meet energy demands with equal propensity (Figures 3.2A, 3.2B). 
RF/6A cells behaved differently under stress. Their cellular metabolic needs  
were met by enhanced glycolysis, with an increase in ECAR of roughly 50%  
over baseline (Figures 3.2C, 3.2D), without any change in OCR. On comparing 
OCR versus ECAR, HRECs moved to a more energetic phenotype (Figure 3.2A) 
under stressed conditions. Meanwhile, RF/6A cells became more glycolytic on 
being stressed (Figure 3.2C).  
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Figure 3.2. Cellular energetic behavior of endothelial cells under metabolic 
stress. Cell energy phenotype profiles of (A) HRECs and (C) RF/6A cells. Open 
box indicates baseline phenotype, filled box indicates stressed phenotype. 
Representative plots of three independent experiments. Some error bars are too 
small to be seen. (B, D) % stressed OCR and ECAR produced over 100 % 
baseline OCR and ECAR. Mean ± SEM, n=3; **p<0.01, ****p<0.0001, two-tailed 
unpaired Student’s t-test. 
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3.3.3 The majority of intracellular ATP is produced from mitochondrial 
respiration  
In order to understand the source of ATP during OCR and ECAR 
measurements, I performed an assay that would distinguish between ATP 
generated by mitochondrial oxidative phosphorylation and glycolysis (Figure 
3.3A, 3.3B). Total cellular ATP generation was higher in RF/6A cells (Figure 
3.3C) with nearly 70% of ATP generation from mitochondria and the remainder 
from glycolysis. For HRECs, mitochondrial ATP generation was higher than that 
in RF/6A cells at 75% (Figure 3.3C). I also assessed the ATP rate index for both 
cell types, with HRECs showing higher ATP production from mitochondrial 
respiration compared to RF/6As, even though both cell types had an index >1, 
indicating cellular energy mostly to be mitochondrial (Figure 3.3D). 
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Figure 3.3. Total intracellular ATP generation. (A) OCR and (B) ECAR kinetic 
traces for RF/6A and HRECs with respective modulators injected at indicated 
time points during assay run. Representative plots from three independent 
experiments. (C) Total ATP generation measured with demarcations indicating 
mitochondrial and glycolytic ATP in the stacked columns. (D) Ratio of 
mitochondrial ATP to glycolysis ATP production rates for each cell type. Mean ± 
SEM, n=3. 
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3.3.4 Optimal Cell Seeding Density Ranged Between 2104 Cells and 4104 
Cells 
 To understand the mitochondrial response to variable cell number, I  
tested three different densities of cells to identify the optimal working range of 
cells for assays (Figures 3.4A, 3.5A). Basal respiration signal increased in 
proportion to increase in cell number (Figures 3,4B, 3.5B). For both cell types, 
4104 cells (100% confluent) had the highest reportable FCCP-induced maximal 
respiration (Figures 3.4C, 3.5C), with no significant change in coupling efficiency 
(Figures 3.4G, 3.5G). Significant changes in proton leak were observed in 2104 
and 4104 HRECs and 4104 RF/6A cells respectively (Figures 3.4D, 3.5D). 
OCR-linked ATP for HREC and RF/6A was significantly higher at 4104 seeding 
density than at lower densities (Figures 3.4E, 3.5E). Spare respiratory capacity 
remained unchanged for HRECs (Figure 3.4F), whereas for RF/6A, 4104 cells 
increased the potential of cells to meet their spare respiratory capacity (Figure 
3.5F). Based on these findings, I opted to work with 2104 cells and 4104 cells 
for all further assays. 
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Figure 3.4. Optimizing cell seeding density for HRECs. (A) representative images 
from three independent experiments of HRECs along with their OCR traces. 
Scale bar = 500 µm. (B) basal respiration, (C) maximal respiration, (D) proton 
leak, (E) OCR-linked ATP, (F) spare respiratory capacity and (G) coupling 
efficiency. Mean ± SEM, n=3; ns – not significant, *p<0.05, **p<0.01, ANOVA 
with Tukey’s post-hoc tests. 
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Figure 3.5. Optimizing cell seeding density for RF/6A cells. (A) representative 
images from three independent experiments of RF/6A cells along with their OCR 
traces. Scale bar = 500 µm. (B) basal respiration, (C) maximal respiration, (D) 
proton leak, (E) OCR-linked ATP, (F) spare respiratory capacity and (G) coupling 
efficiency. Mean ± SEM, n=3; ns – not significant, *p<0.05, **p<0.01, ***p<0.001, 
ANOVA with Tukey’s post-hoc tests. 
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3.3.5 HREC and RF/6A cells Show Comparable FCCP-Induced Maximal 
Respiration 
 To assess parameters that regulate oxidative phosphorylation, I  
performed serial injection of oligomycin, FCCP and complex I and III inhibitors 
rotenone and antimycin and measured cellular oxygen consumption (Figures 
3.6A, 3.6B). Basal respiration and ATPOCR was slightly higher for RF/6A cells 
compared to HRECs (Figures 3.6C, 3.6D). I observed similar OCR for maximal 
and non-mitochondrial respiration as well as spare respiratory capacity (Figures 
3.6E, 3.6G, 3.6H). Similarly, there was a difference in proton leak, with OCR 
measurement higher for RF/6A compared to HRECs (Figure 3.6F). Both HREC 
and RF/6A cells showed comparable coupling efficiency (Figure 3.6I). Coupling 
efficiency indicates how well the protons are utilized during ATP generation and 
also estimates proton leak during oxidative phosphorylation-coupled reactions. 
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Figure 3.6. Characterizing FCCP-induced maximal respiration and key 
mitochondrial parameters. (A) Schematic of data generated in the mitochondrial 
stress experiment. (B) OCR kinetic traces for RF/6A and HRECs.  
Representative plots from three independent experiments. (C-I) Comparison  
of cell types for the parameters: (C) OCR-linked ATP production, (D) basal 
respiration, (E) maximal respiration, (F) proton leak, (G) non-mitochondrial 
oxygen consumption, (H) spare respiratory capacity, and (I) % coupling 
efficiency. Mean ± SEM, n=3. 
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3.3.6 Modulators of Glycolysis Allow for Assessing Glycolytic Capacity  
of Cells 
In order to document cellular glycolysis and glycolytic parameters, I 
measured ECAR in glucose starved cells that were injected with oligomycin and 
glucose analog 2-deoxyglucose (Figure 3.7A) that inhibits the action of 
hexokinase (Figure 3.7B). Glycolysis ECAR measurement was higher in HRECs 
compared to RF/6A (Figure 3.7C), indicating a reduced baseline glycolysis in 
RF/6A cells. As seen previously in Figures 2 and 3, I observed higher glycolytic 
capacity in RF/6A cells compared to HRECs (Figure 3.7D) as well as glycolytic 
reserve (Figure 3.7E) and acidification due to non-glycolytic reactions (Figure 
3.7F).  
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Figure 3.7. Modulators of glycolysis allow for assessing glycolytic capacity of 
cells. (A) Schematic of data generated in the glycolysis stress experiment. (B) 
ECAR kinetic traces for HRECs and RF/6A. Representative plots of three 
independent experiments. (C-G) Comparison of cell types for the parameters: (C) 
glycolysis, (D) glycolytic capacity, (E) glycolytic reserve, (F) non-glycolytic 
acidification and (G) % glycolytic reserve (% of glycolytic capacity rate over 
glycolysis rate). Mean ± SEM, n=3. 
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3.4 Discussion 
Mitochondrial dysfunction is an area of growing interest in ocular 
endothelial cell biology (Kluge et al., 2013). It has become increasingly evident 
from recent studies that components of the ETC like complexes III and IV 
mediate endothelial function during angiogenesis (Vandekeere et al., 2018, 
Diebold et al., 2019). Blocking heme production diminishes glycolytic capacity of 
retinal ECs, as discussed in Chapter 4 (Shetty et al., 2019). Recent taxonomical 
analysis of murine choroidal ECs from neovascularization revealed potential 
metabolic candidates not found in healthy cells, suggesting targeting endothelial 
metabolism could be the way forward in vascular therapeutics (Rohlenova et al., 
2020). To provide a baseline for future studies, I set out to characterize the 
cellular energetic phenotype of endothelial cells that form important cellular 
models for neovascular diseases (Alizadeh et al., 2018). Traditionally, closed 
oxygen sensors like Clark electrodes were employed on isolated mitochondria, to 
assess oxygen consumption and rate of respiration (Wolfbeis 2015). However, 
this technique can often be technically cumbersome and severely restrictive for 
use in intact cells. I made use of a real-time flux analyzer Seahorse, developed in 
the late 2000s, that senses O2 from a monolayer of cells and measures 
respiration as a function of mitochondria. I provide a detailed optimization method 
that can be employed before working with these or other cell types, identifying 
the optimum FCCP dosage and cell seeding density. I detailed the metabolic 
parameters of two of the most widely-used posterior eye endothelial cell models, 
primary HRECs and the RF/6A cell line.  
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FCCP titration was critical as a first step, as the assay measures FCCP-
induced maximal respiration compared to basal respiration of cells (Dranka et al., 
2011). The FCCP concentration that gave the maximal OCR changed 
significantly from one cell type to another, highlighting the importance of 
characterizing the phenotype of each cell type under various experimental 
conditions. Selection of appropriate cell seeding density is important to minimize 
variability in metabolic parameters owing to clumping of cells (over-seeding) or 
changes in morphology due to low confluency (low seeding) (Lange et al., 2012). 
I recommend working with cell number ranges of 2104 and 4104 as lower cell 
numbers were unable to generate accurate maximal respiration, proton leak and 
spare respiratory capacity.  
In cell energy phenotype assays, I observed a difference between HRECs 
and RF/6A cells in their response to metabolic stress. In parallel with these 
results, I saw similar results with the ATP index ratio that signifies the differences 
in energy behavior between retinal and choroidal endothelial cells. This could be 
due to differences in their culture phenotype, one being primary cells isolated 
from humans and the other being an immortalized cell line. Transformed cells 
rely on glutamine metabolism to replenish TCA cycle intermediates in case of 
anaplerosis (DeBerardinis et al., 2007). However, it might also reflect a 
fundamental difference between microvascular cells of retinal versus choroidal 
origin, as already documented for gene expression profiles (Smith et al., 2007). 
My findings were comparable to the metabolic phenotype of other 
endothelial cell systems. HRECs showed similar maximal respiration to bovine 
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aortic endothelial cells (BAEC) (Dranka et al., 2011). Another study observed 
human umbilical vein endothelial cells (HUVEC) with OCRATP between 4-15 
pmol/min (Gupta et al., 2016), compared to nearly 20 pmol/min in our cell 
models, HRECS and RF/6A cells. Similarly, in a glycolysis stress test, HUVECs 
showed basal ECAR of roughly 3 mpH/min and glycolytic capacity of nearly 40 
mpH/min, analogous to HRECs and RF/6A (Doddaballapur et al., 2015; Balogh 
et al., 2018). 
Extracellular flux assays have some limitations. Fluorophore sensors can 
be sensitive to quenching; care must be taken while testing compounds that may 
interfere with fluorescence, namely inclusion of controls without cells and basal 
medium, and calibration of these wells with treated cells (Koopman et al., 2016). 
If treatment leads to loss of cell viability, normalization with protein content would 
be appropriate. Cell viability markers can be used at the end of the assay to 
count the number of viable cells. Basal medium components like glutamine and 
glucose vary between different culture media. Thus, I recommend using 
concentrations during assay basal medium preparation similar to cell culture 
medium concentrations.  
Making use of different mitochondrial inhibitors as well as glycolytic 
modulators not only allows for assessment of metabolic function due to different 
stress cues, but also lets one examine different components directly involved in 
the metabolic pathway. Detecting changes in spare respiratory capacity can 
indicate early signs of stress (Perron et al., 2013). The effects of small molecules 
on cellular metabolism, especially in the case of disease models like 
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hyperglycemia or hypoxia can be compared with the baseline phenotype of these 
endothelial cells as described here. Genetic and pharmacological manipulations 
in endothelial cells and their effect on pathway specific changes in metabolism 
can be examined using the ATP production assay, which has not been a part of 
previous metabolic analyses in ocular or other endothelial cells (Liu et al., 2017; 
Al-Shabrawey, 2017; Xiong et al., 2018). Recent studies of non-ocular tissues 
also indicate endothelial cell specific metabolic changes in pathological 
angiogenesis conditions that can be exploited in a novel approach to therapeutic 
target discovery (Goveia et al., 2014; Schoors et al., 2014; Schoors et al., 2015; 
Eelen et al., 2018). 
Together, my findings in this chapter have built a metabolic profile of key 
ocular endothelial cell types, elucidating their energy phenotype and assessing 
parameters governing both oxidative phosphorylation and glycolytic capacity. I 
have also reported an ATP production rate assay that determines the sources of 
ATP generated in the cell and allows for identifying metabolic switching in 
response to different modulators, compounds, genetic modifications or other 
interventions. These results serve as a reference point for testing various 
experimental conditions and metabolic parameters in the two endothelial cell 
types used here. Moreover, this approach provides a framework for 
characterizing the cellular energetics of different cell types prior to further 
manipulations in Chapter 4, and aid in designing experiments addressing Aim II 
and Aim III. 
 
 63 
CHAPTER 4. HEME SYNTHESIS INHIBITION BLOCKS ANGIOGENESIS BY 
CAUSING MITOCHONDRIAL DYSFUNCTION 
4.1 Summary 
The relationship between heme metabolism and angiogenesis is poorly 
understood. The final synthesis of heme occurs in mitochondria, where FECH 
inserts Fe2+ into protoporphyrin IX to produce proto-heme IX. We previously 
showed that FECH inhibition is antiangiogenic in HRECs and in animal models  
of ocular neovascularization. In the present chapter, I sought to understand the 
mechanism of how FECH and thus heme is involved in maintaining endothelial 
cell function. Heme synthesis inhibition changed mitochondrial morphology in 
endothelial cells. Loss of heme causes a buildup of mitochondrial ROS and 
depolarized membrane potential (ΔΨm). Oxidative phosphorylation and 
mitochondrial complex IV were decreased in HRECs and in mice retina ex vivo 
after heme depletion (Figure 4.1). Exogenous supplementation with heme 
partially restored phenotypes of FECH blockade. The findings presented in this 
chapter provide a previously unknown link between mitochondrial heme 
metabolism and angiogenesis.  
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Figure 4.1. Graphical summary of chapter 4. Heme depletion via FECH  
blockade disrupts key mitochondrial functions like respiration, membrane 
potential, morphology and elimination of reactive oxygen radicals. ETC 
components like complex IV are directly affected due to insufficient incorporation 
of heme in the enzyme catalytic core for complex formation. ΔΨm = membrane 
potential, ROS, reactive oxygen species; I, II, III, IV, ETC complexes.  
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4.2 Background and Rationale 
An imbalance in mitochondrial metabolism has been implicated in the 
development of neovascular diseases catalyzed by aberrant angiogenesis. 
However, the role of heme synthesis in the development of mitochondrial 
dysfunction in neovascular diseases is unclear. As discussed above, 
neovascularization is a common phenomenon seen in vascular diseases like 
cancer, type 2 diabetes mellitus, PDR, ROP, and wet AMD (Friedman et al., 
2004; Hellstrom et al., 2013; Kempen et al., 2004; Kizhakekuttu et al., 2012).  
We previously reported that heme synthesis inhibition is anti-angiogenic in retinal 
ECs in vitro and in animal models of ocular neovascularization. Blocking heme 
production in HRECs decreased proliferation, migration, and endothelial tube 
formation and caused reduced protein expression of total and phosphorylated 
VEGFR-2 (Basavarajappa et al., 2017). This antiangiogenic effect was only seen 
in ocular ECs, while ocular non-endothelial cells were not similarly affected. 
Heme synthesis inhibition was associated with smaller ocular neovascular 
lesions in a choroidal neovascularization mouse model. However, the 
mechanism underlying this effect remains unknown. The final synthesis of heme 
takes place in the mitochondria, when FECH inserts ferrous ion into a precursor 
PPIX to form protoheme (iron-protoporphyrin IX) (Dailey et al., 2017; Nilsson et 
al., 2009; Poulos, 2014). By directly targeting FECH, cells can be depleted of 
heme and heme-containing proteins, with a concomitant build-up of PPIX 
(Atamna et al., 2001; Vijayasarathy et al., 1999). Apart from the role of heme in 
oxygen transport and storage, heme acts as a prosthetic group in many 
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hemoprotein enzymes involved in oxidative phosphorylation, plus cytochrome 
P450s, catalases, and nitric oxide synthase (Chiabrando et al., 2014).   
In the present chapter, I aimed to assess the relationship between mitochondrial 
physiology in human ECs and heme inhibition. I hypothesized that heme 
inhibition would lead to defects in heme-containing enzymes of the mitochondrial 
ETC, and thus affect mitochondrial function of ECs. I show that loss of heme 
altered mitochondrial morphology and dynamics, causing increased ROS levels 
and depolarized membrane potential. These studies reveal that heme synthesis 
is required for EC respiration and COX IV function specifically, and can 
negatively impact glycolytic capacity of ECs. Thus, I characterized a previously 
unknown role of heme in cellular metabolism that facilitates EC function in 
angiogenesis. 
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4.3 Results 
4.3.1 Heme Inhibition Caused Changes to Mitochondrial Morphology and 
Increased Oxidative Stress 
 To block heme production, I used a competitive inhibitor of FECH called 
N-methylprotoporphyrin (NMPP) (Shi and Ferreira, 2006). Blockade of FECH 
with active site inhibitor NMPP (Ki ~ 10 nM) causes accumulation of precursor 
PPIX, as NMPP competes with FECH substrate PPIX for the binding site of the 
enzyme (Table 4.1). We have previously shown that HRECs exposed to NMPP 
showed remarkably reduced proliferation, migration and tube forming ability. 
NMPP was shown to produce a GI50 value of 30 µM in HRECs and 126 µM in 
RF/6A cells. This effect was specific to ECs, with brain microvascular ECs 
showing GI50 value of 39 µM and non-EC ocular cell types having negligible anti-
proliferative effects (Basavarajappa et al., 2017). While NMPP has been used 
widely as chemical inhibitor of FECH, NMPP could have off-target effects in the 
cells. 
  HRECs treated with NMPP showed changes in mitochondrial 
fragmentation and shape (Figure 4.2A). NMPP treated cells had decreased form 
factor values, indicating reduced mitochondrial branching (Figure 4.2B; Figure 
4.3A-F), owing to more highly fragmented mitochondria (Figure 4.2B, inset 
image). Mitochondria appeared less elongated and elliptical in NMPP treated 
HRECs as seen by lower aspect ratio values (Figure 4.2C). To determine 
mitochondrial mass, I used flow cytometry and quantified median fluorescence 
intensity (MFI) of NMPP treated HRECs (Doherty and Perl, 2017). NMPP 
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treatment led to reduced MFI, indicating decreased mass in mitochondria (Figure 
4.2D).  
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Table 4.1. PPIX levels in HRECs treated with NMPP. PPIX levels quantified by 
ultra-performance liquid chromatography in HRECs treated with DMSO control 
and NMPP. This analysis was performed by the Iron and Heme Core, University 
of Utah. 
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Changes in mitochondrial morphology are commonly accompanied by 
transcriptional changes in genes regulating mitochondrial dynamics like the 
fusion-fission proteins (Westermann 2010, Duriaswamy et al., 2019). 
Metabolically active mitochondria undergo fusion events to form large 
interconnected mitochondria, whereas cells under low energy demands consists 
of smaller spherical mitochondria (Collins et al., 2002). Hence, I tested mRNA 
levels of key mitochondrial fusion proteins involved in mitochondrial dynamics, 
MFN2 and OPA1, and found significantly lower levels under FECH blockade 
conditions (Figures 4.2E and 4.2F). Fission regulator DNM1L (encoding Drp1) 
showed no change. I measured mitochondrial specific ROS using MitoSox ROS 
and cells treated with NMPP showed a marked increase in ROS levels (Figure 
4.4A). I quantified this increase using flow cytometry and found a significant 
increase in MitoSox ROS labeled HRECs treated with NMPP (Figures 4.4B-C). 
This effect of elevated ROS levels was also seen in RF/6A cells treated with 
NMPP (Figures 4.4D and 4.4E). This primate cell line has properties of 
chorioretinal ECs (Lou and Hu, 1987), and thus provides corroboration of the 
primary HREC data. 
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Figure 4.2. FECH blockade alters mitochondrial morphology and increases 
oxidative stress. (A) HRECs treated with DMSO or FECH inhibitor NMPP  
stained with MitoTracker green (MTG). Inset images indicate magnified region 
marked in red boxes. Form factor (B) and aspect ratio (C) as quantified using 
ImageJ. Individual data points indicate mean of mitochondria analyzed from  
each of 12 individual cells per treatment group. (D) Quantification of MTG 
fluorescence using flow cytometry and calculated Median Fluorescence intensity 
(MFI). qPCR analysis of mRNA expression under FECH knockdown (E) or 
NMPP treatment (F). Bar graphs indicate mean ± SEM, n=3. Representative 
results from three independent experiments. ns, non-significant, *p<0.05, 
 72 
**p<0.01, ***p<0.001, ****p<0.0001, two-tailed unpaired Student’s t-test. Scale 
bars = 20 µm.  
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Figure 4.3. Morphometric analysis of mitochondria in HRECs (A-D) 
Representative HRECs depicting particle analysis for measuring mitochondria. 
(A, B) Representative slice from Z-stack images showing threshold intensity set 
for DMSO and NMPP treated HRECs. (C, D) Representative slice from Z-stack 
images showing outlines of assessed mitochondria. (E, F) Correlation of form 
factor versus aspect ratio under DMSO and NMPP treatments for the 
representative cells shown above. Scale bars = 10 µm. 
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Figure 4.4. FECH inhibition elevated ROS levels in HRECs and RF/6A cells. (A) 
HRECs stained with mitoSox ROS in red and Hoechst staining in blue. (B) 
Representative fluorescence peaks as measured by flow cytometry followed by 
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(C) quantification of cells positive for red fluorescence. (D) RF/6A cells labeled 
with mitoSox ROS were assessed using flow cytometry. Representative 
fluorescence peaks. (E) Quantification of cells positive for red fluorescence. Bar 
graphs indicate mean ± SEM, n=3. Representative results from three 
independent experiments. ***p<0.001, ****p<0.0001, two-tailed unpaired 
Student’s t-test. Scale bars = 20 µm.  
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4.3.2 Loss of FECH Depolarized Mitochondrial Membrane Potential 
To assess mitochondrial health, I next measured membrane potential 
using JC-1, a polychromatic dye that on excitation forms red aggregates and 
green monomers depending on the energized or deenergized state of the 
mitochondria. Both siRNA mediated knockdown of FECH and chemical inhibition 
using NMPP induced loss of healthy red aggregates and an increase in 
monomers as seen by the green fluorescence (Figures 4.5A and 4.5D). This JC-
1 excitation was quantified using flow cytometry on HRECs labeled with JC-1 
dye, and showed reduced red to green fluorescence ratio, indicative of 
mitochondrial depolarization (Figures 4.5B, 4.5C, 4.5E and 4.5F). RF/6A cells 
also showed depolarized membrane potential after NMPP treatment (Figures 
4.6A-C). 
 
 77 
 
Figure 4.5. Loss of FECH reduced mitochondrial membrane potential in HRECs.  
(A) HRECs stained with JC-1 dye showing green monomers and red aggregates 
under FECH knockdown condition and (D) NMPP treatment. (B) Representative 
dot plots of FL1 versus FL2 channel from three individual experiments, 
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measuring red and green fluorescence using flow cytometry after FECH 
knockdown and (E) NMPP treatment. Red and green arrows indicate quadrants 
expressing FL1-red and FL2-green fluorescent cells. (C, F) Quantification of 
red:green fluorescence from flow experiment. *p<0.05 vs. untreated, one-way 
ANOVA with Tukey’s post hoc tests. Bar graphs indicate mean ± SEM, n=3; 
Scale bars = 20 µm. 
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Figure 4.6. FECH blockade depolarized mitochondria in RF/6A cells. (A) RF/6A 
cells stained with JC-1 dye showing green monomers and red aggregates under 
NMPP treatment. (B) Representative dot plots of FL1 versus FL2 channel 
measuring red and green fluorescence using flow cytometry after NMPP 
treatment. Red and green arrows indicate quadrants expressing FL1-red and 
FL2-green fluorescent cells. (C) Quantification of red:green fluorescence from 
flow experiment. *p<0.05 vs. untreated, one-way ANOVA with Tukey’s post hoc 
tests. Bar graphs indicate mean ± SEM, n=3; Scale bars = 20 µm. 
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4.3.3 Reduced COX IV Protein Expression and Activity Rescued by Hemin 
To determine where heme depletion was influencing mitochondrial 
function, I evaluated protein complexes of the ETC after heme inhibition, as 
complexes II, III and IV contain heme in their prosthetic groups (Kim et al.,  
2012). FECH knockdown resulted in a significant decrease of only Complex IV 
protein levels (Figures 4.7A and 4.7B). NMPP treated cells showed a similar 
decrease in COX IV, and I also found increased expression in COXV ATP 
synthase upon treatment with this small molecule (Figures 4.7A and 4.7C). I  
then examined the heme containing subunit 1 of COX IV and found a significant 
decrease under both knockdown and NMPP treatment (Figures 4.7D-G). 
Enzyme activity of COX IV was also reduced, and total levels of the complex 
were significantly reduced after FECH blockade (Figures 4.7H-K). To confirm if 
these results were dependent on heme, I sought to rescue the phenotype of  
COX IV reduction by external supplementation of heme to the cells. Hemin, a 
stable form of heme, was able to alleviate COX IV protein expression and 
partially rescue COX IV enzyme activity (Figures 4.7L-N). RF/6A cells showed a 
similar rescue phenotype of COX IV enzyme after heme addition (Figures 4.8A-
D). 
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Figure 4.7. FECH inhibition caused reduced COX IV expression, rescued by 
hemin. (A) HRECs under FECH siRNA or NMPP treated conditions were 
immunoblotted for Complexes I-V as indicated. (B, C) Quantification of the blots 
was graphed as shown relative to appropriate control. (D) FECH siRNA treated 
HRECs were probed for COX IV subunit 1 and FECH along with housekeeping 
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control and (E) quantified. Similarly, HRECs treated with NMPP were blotted for 
COX IV subunit 1 (F) with (G) quantification as shown. COX IV enzyme activity 
was measured under FECH knockdown condition (H) and NMPP treatment (J) 
and total COX IV levels were quantified by ELISA for both the conditions (I, K). 
(L, M) COX IV protein expression and quantification under defined conditions.  
(N) COX IV enzyme activity was partially rescued in NMPP treated cells  
exposed to hemin. Immunoblot images representative from three independent 
experiments. Bar graphs indicate mean ± SEM, n=3-4; ns, non-significant, 
*p<0.05, **p<0.01. (B, C, E, G, H-K) unpaired Student’s t-test (M, N) one-way 
ANOVA with Tukey’s post hoc tests. 
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Figure 4.8. FECH inhibition decreases mitochondrial respiration and COX IV 
expression, which is rescued by hemin in RF/6A cells. (A) RF/6A cells treated 
with NMPP were blotted for COX IV subunit 1 with (B) quantification as shown. 
(C, D) RF/6A cells treated with 100 µM NMPP show rescue of COX IV protein 
levels after hemin supplementation. Bar graphs indicate mean ± SEM, n=3; 
*p<0.05, (B) unpaired Student’s t-test; (D) one-way ANOVA with Tukey’s post 
hoc tests. 
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4.3.4 FECH Blockade Reduced Mitochondrial Function of Retinal ECs 
Based on the optimized parameters for bioenergetics of HRECs and 
RF/6A cells described in Chapter 3, I sought to understand whether loss of 
function of an important complex in the ETC resulted in defects in mitochondrial 
respiration. I measured OCR of HRECs after FECH knockdown and observed 
reduced basal respiration (Figures 4.9A, 4.9B). Uncoupler-induced maximal 
respiration was significantly decreased, with a marked reduction also found in 
OCR-linked ATP production and spare respiratory capacity (Figures 4.9C-E). 
Similarly, NMPP treated cells showed a dose dependent decrease in basal 
(Figure 4.9F and 4.9G) and maximal respiration (Figure 4.9H) along with a 
decline in OCR-linked ATP production and spare respiratory capacity (Figures 
4.9I and 4.9J). I saw a similar decrease in mitochondrial respiratory activity in 
RF/6A cells (Figures 4.10A-E). 
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Figure 4.9. Loss of FECH reduced mitochondrial respiration in HRECs. (A, F) 
OCR kinetic traces for HRECs under FECH knockdown or NMPP chemical 
inhibition. (B, G) Basal respiration, (C, H) maximal respiration, (D, I) OCR-linked 
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ATP production, and (E, J) spare respiratory capacity were calculated based on 
OCR curves for the respective treatment group. (A, F) Representative OCR 
curve of three individual experiments. Bar graphs indicate mean ± SEM, n=3; 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (B, C, D, E) unpaired Student’s t-
test (G, H, I, J) one-way ANOVA with Tukey’s post hoc tests. 
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Figure 4.10. Reduced mitochondrial respiration in RF/6A after FECH inhibition. 
(A) Representative OCR kinetic traces for RF/6As under NMPP chemical 
inhibition. (B) Basal respiration, (C) maximal respiration, (D) OCR-linked ATP 
production, and (E) spare respiratory capacity were calculated based on OCR 
curves for the respective treatment group. Bar graphs indicate mean ± SEM,  
n=3; ***p<0.001, ****p<0.0001, unpaired Student’s t-test. 
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4.3.5 Inhibition of FECH Led to Decreased Glycolytic Function 
Microvascular ECs are highly glycolytic compared to other cell types (De 
Bock et al., 2013). As determined in Chapter 3, under mitochondrial stress, both 
HREC and RF/6A cells had increased glycolysis over mitochondrial respiration  
in our system (Figure 3.2, Chapter 3). Hence, I next investigated this key cellular 
energetic pathway in HRECs, by measuring changes in the pH of the 
extracellular medium. Cells were briefly starved in glucose deficient medium, 
followed by induction of glycolysis using a saturating dose of glucose. 
Interestingly, HRECs under siRNA mediated FECH knockdown and NMPP 
treatment each had decreased glycolytic capacity and glycolysis (Figures 4.11A-
C, 4.11E-G). Both conditions depleted glycolytic reserve, as seen by a marked 
decrease in ECAR after 2-DG injection (Figures 4.11D, 4.11H). 
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Figure 4.11. FECH inhibition caused a decrease in glycolytic function. (A, E) 
ECAR kinetic traces for HRECs under FECH knockdown or NMPP chemical 
inhibition. (B, F) Glycolysis, (C, G) glycolytic capacity, and (D, H) glycolytic 
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reserve were calculated based on ECAR curves for the respective treatment 
group. (A, E) Representative ECAR curve of three individual experiments. Bar 
graphs indicate mean ± SEM, n=3; **p<0.01, ***p<0.001, ****p<0.0001,  
unpaired Student’s t-test. 2-DG, 2-deoxyglucose. 
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4.3.6 FECH Inhibition In Vivo Caused Impaired Mitochondrial Energetics in 
Retina 
I further determined if the effect of NMPP had the same phenotype in vivo 
in an intact eye. For this, we administered NMPP intravitreally to mice and 
measured OCR of retina in an ex vivo assay (Figure 4.12A). I found that retinas 
treated with NMPP had a significant decrease in basal respiration and a similar 
decline in maximal respiration (Figures 4.12B and 4.12C). Spare respiratory 
capacity was severely reduced in the retinas of NMPP treated animals compared 
to their vehicle treated counterparts (Figure 4.12D). I also observed about a 30% 
reduction in protein expression of COX IV in the NMPP-treated retinas (Figures 
4.12E and 4.12F). 
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Figure 4.12. FECH inhibition in vivo decreased mitochondrial respiration in  
retina. (A) Representative OCR kinetic traces for retina from animals treated  
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with NMPP. (B) Basal respiration, (C) maximal respiration, and (D) spare 
respiratory capacity were calculated based on OCR curves for the respective 
treatment groups. (E, F) Immunoblot showing COX IV-1 protein expression from 
three pooled retinal tissue lysates from NMPP treated eyes and quantification. 
Graphs indicate mean ± SEM for two tissue punches from each retina per 
treatment group, n=6-7 per treatment condition. *p<0.05, ***p<0.001, unpaired 
Student’s t-test. 
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4.4 Discussion  
Heme synthesis blockade suppresses pathological angiogenesis by  
poorly understood mechanisms. In the present chapter, I sought to investigate 
the effects of heme inhibition on the mitochondrial function of retinal ECs, by 
directly studying heme-containing complexes of the ETC and documenting 
mitochondrial physiology under heme depletion.  
The mitochondrial ETC is a major source of ROS induced by VEGF in 
hyperglycemic and hypoxic cellular environments (Cheng et al., 2011; Pearlstein 
et al., 2002; Wang et al., 2018). In PDR, increased mitochondrial ROS and 
impaired Ca2+ signaling can cause an increase in oxidative stress (Kowluru and 
Mishra, 2015; Pangare and Makino, 2012; Tang et al., 2014; Wang et al., 2018). 
Complex III of the ETC was recently shown to be important for umbilical vein EC 
respiration and thus proliferation during angiogenesis (Diebold et al., 2019). 
Mitochondrial dysfunction in the retinal pigment epithelium and photoreceptors 
have been reported for wet AMD (Barot et al., 2011; Lefevere et al., 2017), but 
evidence in retinal ECs is lacking. Metabolic factors like succinate and 
adenosine, generated from the Krebs cycle and ATP metabolism respectively, 
are proangiogenic for hypoxia-driven neovascularization (Sapieha et al., 2010). 
However, the exact mechanism of how metabolites disrupt mitochondrial 
energetics in ischemic retinal ECs remains unclear (Grant et al., 1999; Sapieha 
et al., 2008).  
Mitochondrial dysfunction in ECs is, potentially, involved in pathological 
angiogenesis. Heme and heme-containing enzymes play a significant role in this 
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process, but the linkage between these phenomena has not been extensively 
explored. Serine synthesis deficiency induced heme depletion in ECs and 
caused decreased mitochondrial respiration and multiorgan angiogenic defects  
in animals (Vandekeere et al., 2018), while heme accumulation in ECs due to an 
altered heme exporter affects angiogenesis and causes endoplasmic reticulum 
stress (Petrillo et al., 2018). Apart from ECs, non-small cell lung carcinoma cells 
with elevated heme synthesis levels had increases in enzyme activities of the 
ETC. Increased production of heme was associated with increased migratory  
and invasive properties of these cells and xenograft tumors in mice (Sohoni et 
al., 2019). Here, I demonstrated that heme depletion by blockade of the terminal 
synthesis enzyme FECH led to defects in COX IV and ETC disruption (Figure 
4.7). Retinal and choroidal ECs alike have increased mitochondrial specific 
oxidative stress, dysfunctional mitochondrial physiology and disruption of 
glycolysis as a result of these defects.  
Changes to mitochondrial morphology can indicate alterations in 
mitochondrial dynamics and cellular function. My findings of reduced form factor 
and aspect ratio after FECH blockade indicate greater fragmentation and 
decreased length (Duraisamy et al., 2019; Picard et al., 2013). Further, reduced 
mitochondrial mass was evident by our flow cytometric analysis. The core 
components of the mitochondrial fusion proteins include MFN2 (outer  
membrane) and OPA1 (inner membrane) (Youle and Bliek 2012). FECH 
knockdown in HRECs reduced MFN2 and OPA1 transcript levels. Reduction of 
these mitochondrial fusion protein marker genes confirms a change in 
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mitochondrial dynamics. An increase in fragmented mitochondria also leads to 
increased ROS levels (Jezek et al., 2018), as confirmed by our results. 
Moreover, disruption of fusion proteins can also lead to an increase in ROS 
levels (Kim et al., 2018), as also evident in our cell model. Loss of membrane 
potential can lead to selective blockade of inner membrane fusion, while the 
fusion of outer membrane can still proceed even without the fusion of inner 
membrane (Westermann 2010). This could explain why I did not observe any 
change in fission gene OPA1 expression in NMPP treated HRECs, but there  
was a decrease in MFN2. This effect is consistent with the smaller, fragmented 
mitochondria we observed, similar to those seen in diabetic mouse coronary  
ECs (Makino et al., 2010). It is possible that FECH knockdown, which causes a 
direct decrease in FECH transcription, is more deleterious to cells than a 
chemical inhibitor like NMPP that only blocks FECH activity while keeping gene 
expression intact. FECH constitutes the iron-sulfur cluster that functions 
independent of the FECH catalytic activity, however, the actual cluster function 
remains unclear (Dailey at al., 2000). While reduced heme biosynthesis can  
itself cause iron-sulfur cluster deficiency (Crooks et al., 2010), identifying a 
structural role to FECH could be interesting to explore in future studies. This 
would potentially explain the differential effect on inner membrane fusion gene 
OPA1 between FECH knockdown versus NMPP treated cells.  
Mitochondrial fission machinery includes DNML1 among other proteins, 
however, for a successful fission event, recruitment of DNML1 and subsequent 
phosphorylation is critical for the fission process (Youle and Bliek 2012). 
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Blockade of fusion and fission proteins often leads to fragmented mitochondria 
and have been implicated in several neurodegenerative and metabolic disorders 
(Liu et al., 2020). I did not observe any change in gene expression of DNML1, 
suggesting that heme deficiency selectively disrupts mitochondrial fusion, while 
fission remains unperturbed. Another important mitochondrial function is 
mitochondrial DNA (mtDNA) transcription of genes encoding complexes of the 
ETC. While it is clear that nuclear encoded genes like those involved in fusion 
are affected after heme depletion, effect on other genes was not investigated in 
the present study. FECH inhibition possibly leads to a compensatory 
overexpression of COX4I1 (COX IV subunit 1) mRNA levels (data not shown), 
however a more thorough investigation to compare transcriptional alterations 
between mtDNA versus nuclear genome should be considered in future. 
Inner mitochondrial membrane potential (ΔΨm) was considerably 
decreased after FECH knockdown or NMPP treatment. This finding was 
explained by my result of reduced COX IV protein expression and activity, which 
might have collapsed the potential gradient and caused a reduced membrane 
potential. My mitochondrial energetics findings further support this result. A 
significant reduction in FCCP-induced maximal respiration indicates defective 
COX IV, which is unable to perform the role of electron transfer. Uncoupling 
brought on by FCCP causes the ETC to rely on COX IV to carry out oxidative 
phosphorylation by the free-flowing electrons (Dranka et al., 2011). Under FECH 
inhibition conditions, FCCP-induced maximal respiration was affected, indicating 
COX IV dysfunction due to heme loss.  
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Figure 4.13. Schematic model of mitochondrial dysfunction on heme loss. Heme 
synthesis begins with the condensation of glycine and succinyl CoA in the 
mitochondrial matrix. The final step is the insertion of ferrous ion into 
protoporphyrin IX (PPIX) – catalyzed by ferrochelatase (FECH) to produce 
protoheme (also known as heme b). Protoheme and its derivatives are available 
for different cellular enzymes, including complexes of the electron transport  
chain (ETC, e = electrons). Heme a is synthesized by sub-hemylation steps, and 
utilized by COX IV for composition of the holoenzyme. Heme synthesis blockade 
by inhibiting the terminal synthesis enzyme FECH leads to COX IV defects and 
disrupts cellular energetics. Mitochondrial dynamics is altered with reduced 
fusion and mass, depolarized membrane potential (ΔΨm) and elevated reactive 
oxygen species (ROS). 
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Heme depletion by directly blocking FECH primarily affected COX IV of  
all the other heme containing complexes of the ETC in ECs of the retina and 
choroid. COX IV subunit 1 contains heme a and a3 (not found in complexes I-III 
and V). Heme a is made in a series of sub-synthesis hemylation steps carried  
out by heme a synthase and is essential for proper folding and stability of COX  
IV (Kim et al., 2012) (Figure 4.13). COX IV is particularly sensitive to FECH 
inhibition-induced heme depletion, possibly affecting the hemylation process 
downstream of protoheme synthesis, leading to a smaller pool of heme a 
(Atamna et al., 2001; Sinkler et al., 2017).  
Recently, it was shown that complex III is essential for EC proliferation 
(but not migration) in macrovascular ECs. Conditional knockout of EC-specific 
complex III led to reduced retinal, lung and tumor neovascular blood vessels 
(Diebold et al., 2019). While it is possible that disruption of COX IV could in turn 
cause functional alterations in other complexes of the ETC, in our system I did 
not observe a significant change in protein expression of other complexes, 
including complex III. For this reason, I did not study individual enzymatic 
activities of complexes I-III and V. Although, it would be interesting to investigate 
whether heme depletion through FECH inhibition could result in loss of enzyme 
function of complexes I-III or V, even in the absence of protein level changes.  
COX10 and COX15, proteins responsible for conversion of heme b 
(synthesized by FECH) to heme a were among the top-scoring genes that 
caused ETC disruption after heme depletion in acute myeloid leukemia cells (Lin 
et al., 2019), further suggesting the significance of heme a supply as a mediator 
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of mitochondrial function, since it is a prosthetic group specifically in COX IV 
holoenzyme. Furthermore, blocking the skeletal muscle specific COX 7a subunit 
of COX IV decreased mitochondrial ATP production in mouse hindlimb muscles. 
Interestingly, this was associated with reduced muscle angiogenesis and 
decreased capillarity (Lee et al., 2012), further supporting a link between COX IV 
and EC function.  
Loss of functional COX IV was restored at least partially by extracellular 
heme supplementation. This suggests that the EC phenotype after FECH 
inhibition is heme dependent and not due to an off-target effect of NMPP or due 
to PPIX buildup/toxicity (Wyld et al., 1997). NMPP caused significant 
overexpression of complex V (not seen under FECH knockdown), which could  
be a secondary effect of damage to COX IV, causing compensatory upregulation 
of ATP synthase (Havlickova-Karbanova et al., 2012; Rolland et al., 2013). Our 
studies previously indicated effects of NMPP and FECH knockdown specific to 
ECs of retina, choroid, brain and umbilical vein, and we did not observe a similar 
anti-proliferative phenotype on FECH blockade in other ocular cell types of non-
endothelial origin (Basavarajappa et al., 2017). However, the phenotype of  
FECH deficiency on ETC complexes in other cell types beyond ECs would be  
an interesting aspect for future exploration. 
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CHAPTER 5. OCULAR PHENOTYPE OF PARTIAL LOSS-OF-
FUNCTION FECH MUTANT MICE 
5.1 Summary 
Heme depletion, through inhibition of terminal synthesis enzyme FECH, 
blocks pathological angiogenesis by causing mitochondrial damage. We 
previously assessed ocular neovascularization in animal models of Fech loss. In 
vivo genetic and pharmacological inhibition of Fech intraocularly led to smaller 
neovascular lesions in the posterior mouse eye. We also confirmed this finding  
in mice with a partial loss-of-function Fech mutation (Fechm1Pas). Biochemical  
and clinical features of Fechm1Pas mice have been documented, where liver,  
bone marrow and spleen were examined. However, the ocular physiology of  
Fechm1Pas mice, under normal conditions, have not been characterized. In the 
present chapter, I aimed to characterize the retinal phenotype of Fechm1Pas mice. 
We studied retinal vasculature of postnatal and adult mice. We assessed 
retinal parameters like mitochondrial bioenergetics, PPIX levels, visual activity 
and histology. We found that homozygous Fechm1Pas mice had pronounced 
buildup of PPIX in the posterior eye with no damage to visual function and 
integrity of retinal layers. These findings provide a baseline retinal phenotype of 
Fech deficient mice and help characterize ocular abnormalities. 
 
5.2 Background and Rationale 
 FECH catalyzes heme production in the mitochondria in the terminal step 
of the heme synthesis pathway (Dailey and Meissner, 2013). FECH inserts  
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reduced ferrous iron into PPIX to produce proto-heme IX. Loss of FECH activity, 
thus, leads to reduced heme production, accompanied by accumulation of 
substrate PPIX. Many intermediates of heme synthesis are porphyrins, known  
for diseases of porphyria caused due to defects in the synthesis pathway 
(Bonkovsky et al., 2013). In humans, diminished FECH activity is associated  
with erythropoietic protoporphyria (EPP), caused due to build-up of PPIX in 
erythrocytes. The main symptom of EPP includes photosensitization of skin due 
to PPIX phototoxicity, and in certain cases, mild anemia and liver damage 
(Rufenacht et al., 1998).  
Fechm1Pas mice have a point mutation in the Fech gene, causing loss of 
Fech activity and PPIX accumulation. This autosomal recessive inherited defect 
in FECH is due to a T to A transversion mutation at nucleotide 293, resulting in a 
methionine to lysine substitution at position 98 of the Fech protein. This leads to 
reduced enzyme activity in heterozygous and homozygous mutant backgrounds, 
compared to wild-type mice. The mutation in the gene was first identified 
following a chemical mutagenesis experiment using ethylnitrosourea (ENU) 
during in-breeding of mice. ENU was injected into the male mice and following 
subsequent mating among littermates for a few generations, the mutation was 
determined to be transmitted as a Mendelian recessive trait. Heterozygous 
mutants are phenotypically normal and exhibit close to 65-70% Fech activity 
without any pathological abnormalities (Tutois et al., 1991). Fechm1Pas 
homozygotes, however, have less than 6-7% Fech activity. Often used as a 
mouse model for EPP, Fechm1Pas homozygous mice have been reported to  
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show photosensitivity and jaundiced liver (Abitbol et al., 2005). Mice with 
complete loss of Fech are embryonically lethal (Magness et al., 2002). 
I previously described how FECH and thus heme is involved in 
neovascularization (Chapter 4). Fechm1Pas mice, in the laser-induced choroidal 
neovascularization model, had angiogenic defects. Fechm1Pas homozygous and 
heterozygous mice developed smaller neovascular lesions compared to WT 
group (Basavarajappa et al., 2017). Acute inhibition of FECH using a chemical 
analog of PPIX, NMPP, showed that this anti-angiogenic effect was due to 
mitochondrial dysfunction, as discussed in chapter 4.  
The molecular mechanism studies underlying some of the pathological 
characteristics of FECH-deficient mice have been heavily focused towards EPP, 
liver diseases, and now pathological angiogenesis. However, the normal ocular 
phenotype of these mutant mice remains uncharacterized. While it is clear that 
Fech deficiency in mice produces smaller neovascular lesions, the normal retinal 
physiology of Fech mutants under non-angiogenic stimulus remains unclassified. 
The objective of this chapter is to perform a thorough characterization of 
the ocular features of FECH-deficient mice and document any ocular 
abnormalities that are phenotypically distinct for the strain. We bred BALB/cJ 
Fechm1Pas backcrossed with wild-type C57Bl/6 mice for five generations. We 
assessed retinal structure, PPIX, vasculature, visual activity and bioenergetic 
phenotypes of Fechm1Pas homozygous, heterozygous and wild-type (WT) 
littermates. These parameters will provide a baseline phenotype, useful for 
manipulations in angiogenesis models. This will also enable differentiating  
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future experimental results under angiogenic pathology from inherent phenotype, 
that is distinct for the Fechm1Pas strain. 
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5.3 Results 
5.3.1 Fechm1Pas Homozygotes Have Pronounced PPIX Buildup in The  
Retina 
 I evaluated retinal structure in vivo using optical coherence tomography 
and captured composite images of retinal layers from anesthetized mice. No 
abnormalities were found in the retinal structure (Figure 5.1A, 1B). Additionally, 
we assessed vascular leakage and performed fluorescein angiography. Retinal 
vessels showed no pathological signs of leakage (Figure 5.1C). In order to 
assess the presence of FECH substrate PPIX in the retinal vasculature, I 
evaluated fundi of littermates from WT, heterozygous and homozygous  
Fechm1Pas mice. PPIX fluorescence was detected in the retinal vasculature of 
adult Fechm1Pas homozygotes, with no PPIX buildup observed in WT and 
heterozygous animals (Figure 5.1D). 
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Figure 5.1. Retinal imaging of Fechm1Pas mice shows PPIX buildup. (A) Retinal 
fundus showing retinal vessels emerging from the optic disc. (B) Representative 
OCT images of sections in red arrows in the adjacent fundus images. (C) 
Representative images of fluorescein angiography. (D) Representative images  
of PPIX fluorescence. ONH = optic nerve head, GCL = ganglion cell layer, ONL  
= outer nuclear layer, RPE = retinal pigment epithelium. Figures A-D were 
generated with the assistance of Sheik Pran Babu Sardar Pasha. 
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5.3.2 Fechm1Pas mice Show No Abnormalities in Individual Retinal Layers 
In order to assess damage to retinal tissue and individual retinal layers, I 
investigated hematoxylin and eosin (H&E) stained retinal sections of littermates 
from WT, heterozygous and homozygous Fechm1Pas mice. Qualitative analysis 
showed no morphological changes. Quantification of retinal thickness showed  
no signs of retinal thinning in all three genotypes (Figure 5.2A). We also counted 
individual nuclei in the ganglion cell layer, inner nuclear layer and outer nuclear 
layer. Thickness (in nuclei) of the respective layers did not show any changes 
between the littermates (Figures 5.2B-E).  
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Figure 5.2. Individual retinal layers of Fechm1Pas mice are normal. (A) 
Representative images of H&E sections of the retina. (B) Quantification of the 
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A/B ratio as indicated. Quantification of the number of nuclei (thickness) in the 
(C) GCL (D) ONL and (E) INL. Analysis was performed with the assistance of 
Neeta Patwari. Mean ± SEM, n=7 eyes, one-way ANOVA, ns = not significant. 
Scale bar = 500 μm. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, 
outer nuclear layer; RPE, retinal pigment epithelium. Figures B-E were  
generated with the assistance of Neeta Patwari. 
 
  
 111 
5.3.3 Retinal Vasculature Indicates No Developmental and  
Physiological Changes 
 In order to assess any developmental defects in the retinal vasculature  
of Fechm1Pas mice, I studied animals at postnatal day 3 (P3) and 8-week old 
retinas. Retinal vessels start growing from the optic disk at P0, spreading  
halfway across the inner retina by P4, and then reach the periphery by P7 
(Fruttiger, 2002). Vasculature was stained at P3 and 8-weeks using isolectin B4 
(Figure 5.3A) and imaged using confocal microscopy. P3 retinas from Fechm1Pas 
mice did not show any signs of pathology after a qualitative assessment. 
Additionally, retinal flat mounts from 8-week old adult animals showed 
physiologically normal retinal vasculature (Figure 5.3B).  
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Figure 5.3. Retinal vessels indicate no developmental and physiological  
changes. (A) Representative images of retinal flatmounts from P3 mice and 
stained with isolectin B4 for vasculature in green. (B) Representative images of 
retinal flatmounts from 8-week old mice stained with isolectin B4. Scale bar = 1 
mm. Figures A and B generated with the assistance of Sheik Pran Babu Sardar 
Pasha. 
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5.3.4 Fechm1Pas Mice Had Comparable Visual Activity 
 Next, I evaluated the visual function of neural retina in Fechm1Pas mice 
using electroretinogram. Dark-adapted mice were stimulated with light flashes 
and scotopic (rod) and photopic (cone) responses were recorded (Figure 5.4A). 
Scotopic a-wave corresponding to the activity of rod photoreceptor cells showed 
no changes in the three genotypic groups. Similarly, b-waves depicting bipolar 
cellular activity for both scotopic and photopic vision showed no defects in the 
three groups (Figures 5.4C-D).  
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Figure 5.4. Fechm1Pas mice had comparable visual activity. (A) Representative 
mean ERG traces of dark-adapted mice. Quantification of (B) scotopic a wave 
(C) scotopic b wave and (D) Photopic b wave (stimulus: scotopic = 2.5, photopic 
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= 25 cd·s/m2). Mean ± SEM, n=6-11 animals, each data point corresponds to 
mean of left and right eye, one-way ANOVA, ns = not significant. 
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5.3.5 Retinal Bioenergetics of Fechm1Pas Mice Normal Among Littermates   
 Given the findings in Chapter 4, I further sought to characterize 
mitochondrial bioenergetics of retinal tissue punches from Fechm1Pas mice and 
establish a baseline OCR of oxidative phosphorylation (Figure 5.5A). OCR 
corresponding to basal respiration showed comparable mitochondrial function in 
all the three genotypes (Figure 5.5B). FCCP uncoupler at 0.5 μM concentration 
was used to collapse the potential gradient and measure maximal activity of the 
ETC. There was no change observed in FCCP-induced maximal respiration in 
the littermates (Figure 5.5C). Similarly, OCR linked to spare respiratory  
capacity, as identified by rotenone and antimycin cocktail, showed no change 
between WT, heterozygous and homozygous Fechm1Pas mice (Figure 5.5D).  
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Figure 5.5. Retinal bioenergetics of Fechm1Pas mice are normal among 
littermates. (A) Representative OCR kinetic traces for retina from Fechm1Pas  
 118 
mice. (B) Basal respiration, (C) maximal respiration, and (D) spare respiratory 
capacity were calculated based on OCR curves for the respective treatment 
groups. Graphs indicate mean ± SEM for two tissue punches from each retina 
per group, n=6-7 per genotype, one-way ANOVA, ns = not significant. FCCP, 
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone. 
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5.4 Discussion 
Loss of FECH activity has been studied by many research groups 
documenting several physical abnormalities, however the role of deficient FECH 
activity in the ocular system remains obscure. We have strong evidence as 
depicted in chapter 3 and in prior publications, to suggest FECH plays an 
important role in ocular endothelial biology. In the first step towards providing a 
direct correlation between FECH and normal ocular angiogenesis in vivo, I 
studied the retinal phenotype of animals with loss-of-function FECH mutation. I 
characterized FECH substrate PPIX retinal levels, retinal morphology and 
structure, vasculature, visual activity and mitochondrial function. 
The ENU mutagenesis approach to induce point mutations can be 
advantageous in identifying the gene and protein function and the downstream 
phenotypic effects caused due to partial or complete loss of function of the gene 
of interest (Justice et al., 1999). Fechm1Pas loss of function point mutation leads  
to deficiency in Fech activity, with mice homozygous for this mutation bearing 
less than 6% activity (Tutois et al., 1991). These Fechm1Pas display inherited  
EPP along with mild liver damage and photosensitivity (Boulechfar et al., 1993). 
Deficiency in FECH function leads to accumulation of substrate PPIX and a 
depletion in heme production (Brady and Lock, 1992). Using the properties of 
fluorescence in porphyrins I first confirmed this phenotype, by directly assessing 
PPIX levels in the eyes of Fechm1Pas mice. For the first time, we have 
demonstrated a method to assess PPIX in vivo, in live animals. This approach 
could potentially be scaled up clinically to assess retinas of EPP patients as  
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well. Fechm1Pas homozygotes show pronounced buildup of PPIX levels in the 
retina, with no indication of leakage from retinal vessels in 8-week old adult  
mice. Mice heterozygous for this mutation showed no detectable PPIX 
fluorescence in the retina, comparable to WT genotype. Heterozygous mutants 
show about 65% Fech activity, which possibly does not result in a significant 
PPIX buildup (Tutois et al., 1991). I have reported visual function of mice with a 
loss-of-function Fech mutation, that was previously undocumented. I did not find 
any abnormalities in the neural retinal activity, suggesting no defect in the 
physiological response to light stimuli and conduction of action potentials  
through the inner retina. Evaluation of the developing retina is limited for these 
parameters, as murine neonatal eyes only open in the second week after birth – 
rendering much live imaging unworkable. 
Constitutive reduction of FECH activity did not result in an aberration to 
retinal mitochondrial oxidative phosphorylation, as seen with my results of 
mitochondrial bioenergetics. Fechm1Pas mice from BALB/cJ background show 
increased activity of respiratory ETC enzymes of complex I, III and IV in the  
liver. Additionally, no change was seen in the activity of mitochondrial  
complexes of the Fechm1Pas mice bred in the C57Bl/6J background (Navarro et 
al., 2005), supporting our finding in the retina. Fechm1Pas mice were backcrossed 
in the C57Bl/6J strain in my study, which may explain lack of any change in  
ETC function. 
It is evident from the bioenergetic results described in Chapter 4, that 
acute inhibition of FECH results in a significant reduction of mitochondrial 
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respiration and COX IV levels. Thus, a constitutive decrease in Fech possibly 
masks a mitochondrial respiratory defect. Thus, I have validated and 
characterized mitochondrial respiration of Fechm1Pas murine retina, under  
normal physiological conditions and in the absence of angiogenic stimuli. 
In order to study whether Fech deficiency led to changes in the 
development of retinal vessels in mice, I studied retinal vasculature from 
neonates at day 3. I observed no signs of aberrant vascularization in the 
developing retina. Adult retinas showed no signs of aberration in the vessels. 
Histologically, retinal layers in all three genotypes maintained normal  
morphology and structure. Nuclei counted in GCL, INL, and ONL were similar in 
all three genotypes, showing no signs of retinal thinning, degeneration or 
detachment of RPE. This further confirms my observations with ERG recordings, 
showing healthy retinal function. Thus, despite the reported phototoxicity of PPIX 
in vivo observed systemically (Libbrecht et al., 2003), Fechm1Pas mice showed 
normal retinal physiology, but with PPIX accumulation in the retinal vessels. 
Interestingly, a case report of an EPP patient showed development of idiopathic 
optic nerve atrophy caused due to vascular obstruction, and vision loss (Tsuboi 
et al., 2007). It is interesting to speculate whether PPIX buildup coincides with 
the atrophy in the fundus in this patient. 
It is important to note however, that an inherent point mutation and further 
backcrossed breeding, may have contributed to metabolic compensation in the 
Fechm1Pas mice. Mouse models of metabolic disorders generated from 
spontaneous mutations, as in the case of Fechm1Pas mice, often make up for 
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reduced cellular activity in subsequent generations (Kennedy et al., 2010). The 
retinal structure, activity and vasculature were largely normal, even with the 
buildup of PPIX. Developmental angiogenesis is normal, as the adult animals 
show no abnormality in the vessels. However, pathological angiogenesis  
appears to be defective in Fechm1Pas heterozygotes and homozygotes 
(Basavarajappa et al., 2017). This raises an important question of whether the 
effect of FECH loss is exclusive to pathologically growing ECs in the vessels. In 
the absence of an angiogenesis stimulus, FECH deficiency does not seem to 
affect existing vasculature, which could be an advantage from a therapeutic 
perspective. These animals can be used as models of pathological  
angiogenesis – as preexisting vessels were found to be physiologically normal.  
In conclusion, while some hepatic and porphyrin-related defects are evident in 
this mouse model, it is still suitable for studies of retinal and choroidal 
neovascularization. 
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CHAPTER 6. DISCUSSION 
6.1 Summary and Discussion 
 In the present chapter, I will highlight key results from Chapters 3, 4, and  
5 and their significance in endothelial function and retinal physiology. To 
determine the mechanism of how heme synthesis is important for the process of 
angiogenesis, I first studied the metabolic energetics of ECs lining the retina and 
choroid. I hypothesized that FECH is a mediator of pathological 
angiogenesis via altering mitochondrial function of endothelial cells. In the 
first step towards addressing this hypothesis, I characterized mitochondrial 
respiration, ATP production, glycolysis, and thus, cellular energy phenotype of 
retinal and choroidal ECs – under normal culture conditions and under  
conditions of metabolic stress. Chapter 3 established for the first time the 
baseline bioenergetic profile of retinal and choroidal ECs and detailed optimized 
parameters that was used for designing all bioenergetic experiments of the 
thesis. Chapter 4 covered how FECH inhibition affected EC metabolic  
energetics and elaborated how key mitochondrial physiological processes were 
affected (Figure 6.1). Heme depletion due to FECH blockade directly affected  
the ETC by decreasing COX IV function. Finally, in chapter 5, I studied Fech-
deficient mutant mice (Fechm1Pas) and characterized their retinal physiology.  
This helped in understanding the contribution of Fech in vivo to developmental 
and adult vessel structure. Fechm1Pas mice had pronounced PPIX buildup with 
normal visual function, mitochondrial respiration and histology of retinal layers. 
Despite some limitations, my results identify a novel role of heme in the process 
of ocular angiogenesis and provide an exciting avenue to pursue future studies. 
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Figure 6.1. Schematic diagram of the heme synthesis pathway in the 
mitochondrion and effect of heme inhibition through intermediate enzymes. 
(Figure adapted from the following submitted manuscript: Shetty, T., and  
Corson, T.W. Mitochondrial heme synthesis enzymes as therapeutic targets in 
vascular diseases) 
 
6.1.1 Heme and Endothelial Cells 
Over five decades of heme discovery, and subsequent studies uncovering 
the synthesis pathway, has highlighted the contribution of heme to physiological 
cellular processes. However, our studies were the first to link heme directly to 
neovascularization in 2017. The Corson Lab first screened the effects of an anti-
angiogenic small molecule derivative called cremastranone against retinal ECs 
(Lee et al., 2014). One of the cellular targets of cremastranone was identified as 
FECH. FECH is a mitochondrial enzyme responsible for inserting ferrous iron  
into PPIX in the final step of the heme biosynthesis pathway to produce heme 
(Figure 1). Our studies validating FECH inhibition, through chemical inhibition 
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and genetic knockdown approaches, found that heme depletion through 
blockade of the terminal catalyzing enzyme FECH, was anti-angiogenic to ECs  
in vitro and in animal models of neovascularization. Retinal and choroidal ECs 
showed significant reduction in angiogenesis-like properties like proliferation, 
migration, and tube formation. ECs showed reduced expressions of activated 
VEGFR-2 and heme-containing eNOS. These effects were exclusive to ocular 
endothelial cells and were not observed in ocular non-ECs like retinoblastoma  
Y-79, retinal pigment epithelium ARPE-19 and uveal melanoma 92-1 cells.  
 Fech inhibition in vivo in models of retinal and choroidal 
neovascularization resulted in fewer neovascular blood vessels compared to 
vehicle. Fechm1Pas homozygous mutants had reduced pathological angiogenesis 
compared to heterozygous mutants, and both genotypes had lower neovascular 
proliferation in comparison to wild-type animals. Significant overexpression of 
FECH was observed in neovascular tufts and regions of angiogenic vessels in 
the retina and choroid. A similar FECH overexpression was observed in human 
patient samples of wet-AMD when compared to age-matched healthy individuals 
(Basavarajappa et al., 2017). These results suggest that heme synthesis is 
crucial to the mechanism of pathological angiogenesis, however prior to the 
current work, the exact mechanism of how heme is essential to 
neovascularization in the eye remained unestablished. 
  
 126 
6.1.2 Mitochondrial Physiology of Ocular Endothelial Cells 
During mitochondrial respiration, oxidation of substrates is coupled to 
phosphorylation of ADP to ATP, termed as coupling efficiency (Toyabe et al., 
2011). A leak in protons across the inner mitochondrial membrane can lower this 
coupling efficiency, resulting in incomplete utilization of oxygen and an overall 
reduced ATP production by ATP synthase. Under normal culture conditions, both 
retinal and choroidal ECs showed nearly 80% coupling efficiency, indicating a 
healthy state of the proton gradient maintained by the ETC complexes (Figure 5, 
Chapter 3). However, FECH inhibition resulted in depolarized membrane 
potential and reduced oxygen coupled ATP synthesis, indicating proton leak, a 
collapsed potential gradient and suggesting a dip in coupling efficiency. Thus, a 
sufficient supply of heme is needed for maintaining optimal coupling efficiency 
and healthy membrane potential for energy production. The loss of potential 
gradient of the ETC could also contribute to production of reactive oxygen 
radicals that can lead to oxidative stress (Zorov et al., 2014).  
 Retinal and choroidal ECs had a higher mitochondrion-coupled ATP 
production versus ATP produced through the glycolysis pathway (Figure 2, 
Chapter 3). Retinal and choroidal ECs had an ATP rate index of >1, indicating 
cellular ATP to be derived majorly from the mitochondria (Figure 3, Chapter 3). 
Nearly 70% of cellular ATP came from aerobic mitochondrial respiration, 
highlighting the significance of oxidative phosphorylation to EC metabolism,  
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even in the absence of an angiogenesis stimulus. On evaluating mitochondrial 
respiration after inhibition of heme synthesis, ECs had diminished mitochondrial 
respiration and low spare respiratory capacity. Additionally, FECH deficiency  
also resulted in a decline in the glycolysis pathway, leading to reduced glycolytic 
capacity and glycolytic reserve of ECs. During one cycle of ATP synthesis, 
glycolysis donates NADH to the ETC for electron transfer. It is possible that this 
could be due to a disrupted feedback loop between oxidative phosphorylation 
and glycolysis, both major sources of ATP for ECs (see below).  
Loss of FECH activity decreases mitochondrial ATP production (Figure 4, 
Chapter 4), explaining why heme loss is anti-proliferative for microvascular ECs 
(Basavarajappa et al., 2017;Vandekeere et al., 2018). Reduced ATP could affect 
processes of proliferation and migration steps during angiogenesis. A shutdown 
of two major energetic pathways in the cell suggests a severe metabolic crisis. 
However, it would be interesting to investigate whether this results in an 
activation of other quiescence or stress-inducible metabolic factors and  
pathways like PGC1α, fatty acid oxidation, or amino acid degradation (Celotto  
et al., 2011). For instance, the TCA cycle donates succinyl-CoA, and heme 
synthesis is initiated with the condensation of succinyl-CoA and glycine. Thus, it 
is tempting to speculate that reduced heme synthesis can damage this system 
and in turn cause a decline in ETC and glycolysis mediated ATP production. 
However, heme depletion is not cytotoxic to ECs, and so it would be interesting 
to explore activation of alternative pathways like autophagy.   
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6.1.3 ETC Function After Heme Deficiency 
In chapter 3, I documented the activity of the ETC of ECs and thus, 
mitochondrial function, by directly measuring oxygen consumption of ECs in real 
time, using an extracellular flux analyzer. Under metabolic stress, retinal ECs 
have an active mitochondrial respiration, while choroidal ECs are more glycolytic 
metabolically. I used this finding and studied ETC function in Chapter 4 under 
conditions of heme depletion through FECH blockade. After FECH inhibition, 
oxygen consumption by the ETC complexes was decreased in both retinal and 
choroidal ECs, and this resulted in a diminished oxidative phosphorylation of the 
ETC. Consistent with my results, recent work (Vandekeere et al., 2018) revealed 
that inhibition of the serine synthesis enzyme phosphoglycerate dehydrogenase 
(PHGDH) reduced glycine (substrate for the first step of the heme synthesis 
pathway), leading to an indirect decrease of heme enzymes and an eventual 
reduction in heme production in ECs. This also caused mitochondrial defects like 
reduced respiration, smaller mitochondria, increased fission, reduced fusion, and 
elevated mitophagy. 
Vandekeere et al. also studied heme inhibition in macrovascular ECs by 
chemically blocking the second synthesis enzyme ALAD, and observed a decline 
in complex IV activity and ATP production coupled to oxygen consumption 
(Vandekeere et al., 2018). In another study performed on macrovascular ECs, it 
was found that endothelial tip cells are less glycolytic than non-tip cells and 
switch to mitochondrial activity during angiogenesis (Yetkin-Arik et al., 2019). 
Neonatal mice with silenced PHGDH had reduced retinal vascularization and 
 129 
reduced vessel area in the brain, heart and kidney. Additionally, another group 
demonstrated that complex III is essential for EC proliferation (but not migration) 
in macrovascular ECs. Conditional knockout of EC-specific complex III led to 
reduced retinal, lung and tumor neovascular blood vessels (Diebold et al., 2019). 
The above-mentioned studies incorporate these in macrovascular ECs, in 
contrast to or studies in microvascular ECs of the retina and choroid. 
Furthermore, heme inhibition in macrovascular ECs via FECH blockade did not 
result in similar anti-angiogenic effects (Basavarajappa et al., 2017). The 
differential phenotypes of heme loss in microvasculature versus 
macrovasculature remain unclear and solicit further studies (Ghitescu and 
Robert, 2002; Sandoo et al., 2011).   
 Heme is an essential cofactor in the complexes of the ETC. Complexes II 
and III have hemes b and c respectively, whereas complex IV has two heme a 
groups (Kim et al., 2012). Subunit I of complex IV contains both groups of heme 
a and FECH inhibition in retinal ECs resulted in a decreased expression of COX 
IV subunit I specifically, with negligible effects on other complexes of the ETC 
(Figure 7, Chapter 4). This suggests that FECH loss particularly impacts heme a 
biosynthesis and thus the only heme a containing protein complex in aerobic 
organisms – complex IV. Heme a carries out electron transfer in the catalytic 
core of complex IV and also facilitates assembly of subsequent subunits into the 
COX IV multi-subunit complex (Hederstedt, 2012). Thus, heme depletion in ECs 
potentially leads to improper formation of COX IV subunits and may contribute to 
generation of reactive oxygen radicals due to a de-regulated ETC (Chapter 4). 
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RF/6A had slightly different energy needs than HRECs (Figures 5-6, Chapter 3), 
however RF/6A cells showed the same decrease in OCR-maximal respiration, 
spare respiratory capacity and loss of membrane potential on heme loss. 
 Fechm1Pas littermates have normal mitochondrial respiration, but it is 
possible that metabolic compensation is contributed by glycolysis or other energy 
pathways. Such an analysis of glycolytic capacity was not done in my study. It 
would be useful to examine levels of glucose uptake and serum levels of lactate, 
lipids and hepatic enzymes to understand metabolic factors compensating lack of 
Fech activity in the homozygous mutants. Adult Fechm1Pas cannot mount a 
sufficient angiogenic response (Basavarajappa et al., 2017), indicating 
insufficient energetic needs as one of the reasons for reduced neovascularization 
in the choroid. It would be interesting to profile the energetic state of ECs 
undergoing pathological angiogenesis, as in the Basavarajappa et al., study, by 
isolating microvascular ECs and assessing them in vitro. Another explanation for 
observing normal mitochondrial bioenergetics in Fechm1Pas mutants, is that 
energy demands possibly switch only after an angiogenic stimulus or insult. This 
explains why pre-existing vessels are normal in growth, but defective during neo-
vessel formation. One way to study this would be to induce angiogenesis 
mimicking physiological conditions of either hypoxia, high glucose or injury to 
Bruch’s membrane in Fechm1Pas mutants of 6-month age groups and then assess 
the energetics of ECs from these models. 
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6.1.4 Therapeutic Potential of Targeting Heme Synthesis in 
Neovascularization 
Current therapeutic strategies targeting mitochondria involve key functions 
like mitochondrial division (Cassidy-Stone et al., 2008), ROS formation 
(Dhanasekaran et al., 2004), and metabolism (Mather et al., 2001; Csiszar et al., 
2009) for age-related neurodegenerative diseases like Alzheimer’s, Parkinson’s, 
and Huntington’s (Lane et al., 2015). Meanwhile, anti-VEGF therapies remain 
classic biologics used for neovascular diseases such as wet AMD, PDR, and 
multiple cancers (Jain, 2014). Until our and others’ work described in this thesis, 
there was no rationale for targeting heme synthesis as neovascularization 
therapy. But given the specific antiproliferative effects of FECH blockade in 
microvascular ECs, FECH inhibitors like N-methyl protoporphyrin have 
demonstrated potential in targeting neovascular pathologies, both in vitro and in 
the OIR mouse model (Basavarajappa et al., 2017; Sardar Pasha and Corson, 
2019). Novel, drug-like FECH inhibitors are also a possibility (Corson et al., 2019; 
Sishtla et al., 2019). 
Repurposing existing drugs for pathological angiogenesis also holds 
promise towards this end. Griseofulvin, an FDA-approved anti-fungal drug, has a 
long-known off-target effect of FECH inhibition (Brady and Lock, 1992; Liu et al., 
2015). It has anti-angiogenic effects in retinal ECs, blocking proliferation, 
migration and tube formation in vitro and reducing neovascularization in vivo 
comparable to intraocular anti-VEGF treatment, in both OIR and L-CNV mouse 
models (Basavarajappa et al., 2017; Sardar Pasha and Corson, 2019). Isoniazid, 
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an anti-mycobacterial drug, decreases FECH expression while upregulating 
ALAS1 (Brewer et al., 2019), and thus could be tested for potential anti-
angiogenic activity in neovascularization models. Other inhibitors of heme 
synthesis used in vitro include succinylacetone and salicylic acid that block ALAD 
and FECH respectively (Giger and Meyer, 1983; Gupta et al., 2013), however 
their use in preclinical angiogenesis models remains to be investigated. 
Targeting mitochondrial proteins directly involved in ETC activity has 
limitations as well, with a direct consequence on mitochondrial function. 
However, extracellular supplementation of hemin (a more stable form of heme) is 
able to normalize some of the mitochondrial physiology after FECH loss, like 
eNOS levels, complex IV activity, and ETC function (Basavarajappa et al., 2017; 
Vandekeere et al., 2018; Chapter 4). Effect of FECH blockade can be titrated, 
with a dose dependent decrease in angiogenesis features observed in animal 
models and ECs in culture. Homozygous Fechm1Pas mice have significantly 
reduced neovascular lesions, compared to heterozygous Fechm1Pas mice. And 
heterozygotes themselves have reduced lesions compared to wild-type 
(Basavarajappa et al., 2017), suggesting a window of FECH antiangiogenic 
effects without toxicity. However, complete loss of Fech and Alas1 are 
embryonically lethal to mice (Magness et al., 2002; Chiabrando et al., 2014a), 
highlighting the importance of modulating heme inhibition carefully.  
 Oral supplementation of heme, while still achieving therapeutic 
antiangiogenic effects of inhibitors, could be considered (Luan et al., 2017). In 
order to limit systemic toxicity, it would be helpful to localize therapeutic 
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formulations to pathological tissue wherever possible. For example, in ocular 
neovascularization, therapeutic agents could be delivered through intravitreal or 
subretinal injection (Basavarajappa et al., 2017), or even as eyedrops if 
formulation allows; this is a promising area for future work. Therapeutic targeting 
specific to ECs could be included in drug delivery systems (Kawahara et al., 
2013), since systemic deficiency in heme synthesis enzymes can lead to 
porphyria. For example, erythropoietic protoporphyria is caused by toxic buildup 
of PPIX (Gouya et al., 1999). The phototoxic PPIX can be detrimental to cells, 
and is manipulated in photodynamic therapy (PDT) (Krammer and Plaetzer, 
2008). However, it is unlikely that PPIX itself mediates anti-angiogenic effects, as 
ALA-PDT relies heavily on uptake of ALA (Wachowska et al.). Moreover, as 
noted, hemin is able to rescue anti-angiogenic effects in ECs, even in the 
presence of PPIX build-up, suggesting that this mechanism is heme dependent 
and not due to PPIX toxicity. 
 
6.2 Limitations 
6.2.1 Cell Culture Models 
Experiments in vascular endothelial cells, in vitro, are restricted by the use 
of primary cultures (except for RF/6A explained below). Primary cultures are 
beneficial to chart out phenotype closest to in vivo physiology. However, primary 
cultures permit use of cells only for a finite number of passages, owing to cellular 
senescence. Thus, design of studies involving stable knockdown using shRNA 
constructs are limited in retinal ECs. Furthermore, retinal ECs are hard to 
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transfect and transfection efficiency remains low in these primary microvascular 
cells. Thus, transient knockdown using siRNA approach was best suitable for my 
experimental set-up of FECH knockdowns. Transient expression of molecules 
meant optimizing knockdown levels to the same efficiency, every single time, to 
reproduce similar levels of heme synthesis depletion, and this introduced further 
technically laborious methods and potential variability in results. In addition, it is 
important to note that I used a universal negative control rather than a scrambled 
negative control of the FECH siRNA. Immortalization of endothelial cell lines is 
rare and often times, cells are found to lose key vascular molecular markers, 
suggesting loss of endothelial properties in culture (Stewart et al., 2011). In the 
case of the RF/6A choroidal endothelial cell line, these are immortalized cultures 
of non-human primate origin. Choroidal endothelial cells are technically 
challenging to isolate and characterize for experimental studies. Certain 
protocols require isolation directly from human donor eyes, which is an additional 
limiting factor. Moreover, during the course of my experimental studies in RF/6A, 
another research group demonstrated that RF/6A cells failed to exhibit significant 
distinguishing markers characteristic of ECs, and thus angiogenesis-related 
studies with these cells should be interpreted with caution (Makin et al., 2018). 
As an alternative, recently a study demonstrated immortalization of choroidal 
cells using an endothelial promoter driving genes required for immortalization, 
which could be considered for use (Giacalone et al., 2019). Additionally, 
choroidal cells can be isolated from bovine eyes.  
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 FECH overexpression was not studied in the present study design, 
Transfection of a myc-tagged FECH construct in primary ECs were unsuccessful 
over several attempts during the course of my study (data not shown). Another 
limitation to consider is the use of ECs in isolation, and without the presence of 
governing factors, naturally present under physiological conditions. For instance, 
ECs of the neo-micro vessels are often covered by pericytes, whereas the larger 
macrovascular ECs contact smooth muscle cells. Studies suggest there is 
regulated interaction between pericytes and ECs during the steps of 
angiogenesis (Ribatti et al., 2011). Thus, a lack of true in vitro conditions that 
mimic vasculature in vivo is also a limiting factor in my studies. 
 
6.2.2 Animal Models 
 As discussed in Chapter 5, complete knockout of Fech in mice is 
embryonically lethal. For this reason, I considered an acute exposure to NMPP, 
restricted to the eye with an intravitreal administration, for Fech inhibition in vivo 
in Chapter 4. Given the wide use of Fechm1Pas mice as model organisms of 
porphyria, I employed use of Fechm1Pas mice for later studies and sought to detail 
the ocular features of this model. Long-term aging studies were lacking in my 
studies, and additional time points of 6 months and/or 8 months, would be more 
correlative of aging neovascular diseases. It would be useful to generate an 
inducible Fech knockdown model. For example, transducing an endothelial-
specific vector containing an shRNA Fech construct in a C57Bl/6 mouse, with an 
inducible promoter could be considered. This would address issues of metabolic 
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compensation and at the same time, allow studying direct consequences on 
retinal function in vivo. Furthermore, ex vivo approaches could be pursued using 
such a model, to further characterize molecular features of ECs during 
angiogenesis. Similarly, Fech overexpression plus PPIX supplementation, would 
also facilitate studies understanding the mitochondrial function in case of heme 
synthesis overdrive. Increased heme production might increase activities of ETC 
complexes, leading to increased ATP production and mitochondrial respiration. 
Mitochondrial biogenesis could also increase in response and mitochondria might 
potentially undergo increased fusion as a result of increased energetics. 
Furthermore, heme synthesis should be characterized in other models of 
angiogenesis currently used for neovascular studies. For example, laser-induced 
choroidal neovascularization and oxygen-induced retinopathy models should be 
studied to elucidate levels of heme, heme enzymes and ETC function. 
 
6.2.3 Heme Blockade 
 Since heme is important in many different cellular processes, one 
important limitation of this work is introducing off target effects, due to the 
presence of many hemoproteins in the cell. This can interfere with the 
mitochondrial phenotype and becomes difficult to distinguish between effects 
exclusive to heme depletion versus off target effects. One way to overcome this 
would be to introduce small molecule inhibitors of heme enzymes (like NMPP), 
specifically targeting mitochondria (similar to siRNA), and thus minimizing 
cytosolic damage. This would also help clarify whether cytosolic hemoproteins 
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contribute to anti-glycolytic effects, and the regulation between mitochondrial 
metabolism and glycolysis due to heme. In contrast to reduced heme, excess of 
heme is also toxic to microvascular retinal ECs. Exposure to hemin for longer 
durations killed cells. Thus, experiments with hemin rescue in Chapter 4 were 
limited and complete rescue of COX IV activity levels was not observed, owing to 
hemin toxicity.  
 
6.3 Future Directions 
6.3.1 Role of Heme Metabolism in Glycolysis 
Heme depletion significantly reduced glycolysis in retinal and choroidal 
ECs as described in Chapter 4. While it is possible that inhibition of oxidative 
phosphorylation resulted in a disruption of the glycolysis pathway, detailed 
analysis of how FECH blockade can influence glucose metabolism warrants 
further studies. Additional experiments characterizing glucose metabolism and 
glycolysis pathway after FECH inhibition or heme depletion are needed. Studies 
determining parameters like lactate production, C-labeled glucose uptake, GLUT-
1 expression, NAD+/NADH ratio, after FECH blockade can address this further. 
Furthermore, expression levels of glycolysis enzymes regulating different steps in 
the pathway like hexokinase, aldolase, phosphofructokinase, pyruvate 
dehydrogenase, directly after heme synthesis inhibition can also be examined. 
Glyceraldehyde-3-phosphate (GAPDH) was recently demonstrated to be a 
heme-binding enzyme and acts as a chaperone for labile heme in the cytosol 
(Fleischhacker and Ragsdale, 2018; Sweeny et al., 2018). Disruption of this 
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heme-binding residue in GAPDH was found to reduce insertion of cytosolic heme 
into iNOS. It would be interesting to investigate whether a decrease in heme pool 
due to FECH blockade has a mechanistic link to glycolysis via the action of 
GAPDH. Is it possible that heme synthesis pathway and glycolysis pathway have 
an internal feedback inhibition in ECs? One way to answer this question would 
be to test activity of key heme enzymes like FECH, ALAS2 and heme-containing 
mitochondrial enzymes like complexes III and IV after introducing a heme-
residue dead-GAPDH mutant construct in ECs. Additionally, GAPDH activity can 
be measured after blockade of heme synthesis via inhibition of FECH and ALAD. 
These experiments will potentially address links between heme, ETC and 
glycolysis and elaborate on the role of heme in cytosolic metabolism.  
During angiogenesis, ECs are known to derive the majority of their ATP 
from glycolysis (Fitzgerald et al., 2018). However, EC tip cells have recently been 
reported to be less glycolytic during angiogenic cell differentiation (Yetkin-Arik et 
al., 2019). It would be interesting to induce angiogenesis in ECs in a 3D model, 
using VEGF-A as stimulus, and using CD34+ as marker, and sort tip cells from 
non-tip cells. Additionally, energy phenotype (as described in Chapter 3) of these 
tip cells compared to non-tip cells should be determined. It is clear that heme 
contributes to both mitochondrial as well as glycolytic metabolism, hence it would 
be helpful to conduct these experiments under conditions of FECH knockdown or 
overexpression. This will directly address how heme synthesis facilitates energy 
generation in tip cells during the process of angiogenesis.  
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 Another key enzyme related to heme is heme-oxygenase (HO-1 and HO-
2), responsible for heme catabolism. Studies found some correlation between 
expression levels of HO isozymes and glycolysis enzyme phosphofructi-2-kinase 
(PFKFB4). Glucose deprivation in hepatocyte HepG2 and retinal pigment 
epithelium cells led to reduced expression of HO-1, HO-2 and PFKFB4 mRNAs 
(Li et al., 2012). HO-2 deficient mice were found to have reduced insulin and high 
glucose along with an impairment in endothelial function in the animals (Sodhi et 
al., 2009). It would be interesting to examine whether heme depletion negatively 
regulates HO-1/2 levels, and whether this in turn leads to a decrease in 
glycolysis through PFKFB4. Glucose metabolism in Fechm1Pas could also be 
studied to investigate whether Fech deficiency in vivo leads to defects in 
glycolysis and HO-1 metabolism. However, metabolic compensation in these 
mice, as seen in Chapter 5 for mitochondrial respiration, should be considered. 
 
6.3.2 Heme Synthesis in Vasculogenesis 
Chapters 4 and 5 provide detailed evidence of the contribution of heme in 
pathological angiogenesis in retinal and choroidal ECs. However, this brings in 
question the role of heme in tumor angiogenesis. Increased heme synthesis was 
found to contribute to increased tumorigenic properties of non-small cell lung 
carcinoma cells (Sohoni et al., 2019). However, how heme functions in postnatal 
vasculogenesis or in the process of tumor angiogenesis remains under-studied. 
Endothelial progenitor cells (EPCs) have been demonstrated to contribute to 
endothelium in tumors, and areas of revascularization in ischemia (Aghi and 
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Chiocca, 2005). Bone marrow-derived EPCs, the adult version of embryonic 
angioblasts, have been found to be mobilized by VEGF. Experimental studies 
show that bone marrow-derived EPCs are capable of forming blood vessels in 
vivo, to some extent. In a laser induced choroidal neovascularization model, 
GFP+ bone marrow cells were transplanted, before introducing laser injury. This 
led to contribution of nearly 50% of blood vessels by the bone marrow derived-
EPCs in the choroidal vessels (Espinosa-Heidmann et al., 2005). Similarly, in a 
lung carcinoma tumor model, bone marrow transplant contributed to more than 
80% of blood vessels in the tumors (Lyden et al., 2001). This raises an important 
question, does heme synthesis play a similar role, metabolically, in the 
functioning of EPCs similar to microvascular and macrovascular ECs?  
 HO-1 was found to induce an increase in the plasma levels of circulating 
EPCs in a mouse model of atherosclerosis (Wu et al., 2009). HO-1 knockout in 
diabetic mice caused a decline in EPCs and reduced the angiogenic potential of 
EPCs derived from these mice (Grochot-Przeczek et al., 2014). Interestingly, 
hemin induced neovascularization in vivo and was found to promote proliferation 
and endothelial gene expression in EPCs in culture (Wang et al., 2009). 
Considering these links between heme and EPCs, it would be interesting to study 
heme synthesis and elaborate on EPC metabolism. Studies on mitochondrial 
respiration and glycolytic pathway can be performed in EPCs after FECH 
knockdown, chemical inhibition, or in EPCs derived from bone marrow of 
Fechm1Pas mice. Additional inhibitors like succinyl acetone can also be included, 
to create conditions of heme depletion. VEGFR2 expression along with 
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expression of angiogenesis signaling proteins can be measured. Furthermore, 
overexpression of FECH or ALAS2 in EPCs can be tested to investigate whether 
increased heme synthesis elevates angiogenic potential of EPCs in vitro or in 
vivo. Hemin can be formulated for delivery intraocularly, and injected in an 
oxygen-induced retinopathy model, to determine whether hemin induces 
revascularization of avascular regions commonly found in this model.   
 Similarly, tumorigenic cells can be examined for activity of heme and ETC 
enzymes. Additionally, FECH loss or mutation can be tested in tumor models like 
retinoblastoma, and mitochondrial function can be further examined.  
 
6.3.3 Heme in Degradation Pathways 
Another aspect, that studies detailed in this thesis do not cover, is the 
contribution of heme depletion to the activation of autophagy related pathways 
and damage to proteasomal degradation. While FECH inhibition in retinal ECs 
did not cause apoptosis (Basavarajappa et al., 2017), examination of autophagy 
was not done in the study. Severe damage to mitochondrial function including 
morphology, ETC activity, membrane potential can disrupt mitochondrial 
homeostasis leading to induction of autophagy. Heme depletion due to blockade 
of serine synthesis in ECs increased mitophagy by increasing expression of 
Parkin in the mitochondrial fractions (Vandekeere et al., 2018). Similar studies, 
after loss of heme in retinal ECs, and determining expression of proteins like LC3 
and Parkin, will help address activation of the autophagy pathway (Mizushima, 
2007). 
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 Increased intracellular heme can lead to toxicity, and it has been 
demonstrated that acute heme levels, in the absence of HO-1, can activate the 
ubiquitin-proteasome system (UPS), to sequester heme into vacuoles for 
elimination (Vallelian et al., 2015). Interestingly, recent studies have found that 
both autophagy and proteasomal degradation systems are potentially linked, 
owing to crosstalk mechanisms (Lilienbaum, 2013). Thus, it would be interesting 
to explore, in case of reduced heme synthesis, whether there is an increase in 
autophagy-related proteins, and whether this leads to a shutdown of the UPS, in 
response. Furthermore, if reduced heme decreases HO-1 expression in the cells, 
this could also alter cues to the degradation systems and raise the question of 
how autophagy and UPS contribute to EC dysfunction. 
 
6.3.4 Heme and Neurodegeneration 
Heme may have some implications in neurodegenerative diseases and 
studies have shown a correlation between heme and mitochondrial damage in 
neurons. Deficiency of heme synthesis impairs neurite growth, and increases cell 
death of neuroblastoma cells, astrocytoma cells, and rat primary hippocampal 
neurons (Atamna et al., 2002; Zhu et al., 2002). Apart from reduced heme, 
excess heme is also toxic to neuronal health. After intracerebral hemorrhaging, 
hemoglobin and free-heme are exposed to surrounding tissues and cause 
activation of inflammation, lipid peroxidation, and neuronal apoptosis (Ma et al., 
2016; Righy et al., 2016). Furthermore, a defect in heme sequestration damages 
myelination in mice, and defective heme export also decreases survival of 
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SHSY5Y neuronal cells (Chiabrando et al., 2016). Mitochondrial dysfunction in 
neurodegeneration includes defective calcium homeostasis, mtDNA transcription, 
mitophagy, apoptosis, dynamics and metabolism. For example, in case of 
Alzheimer’s disease (AD), reduced heme synthesis was observed in temporal 
lobes of patients, as a result of amyloid-β binding to heme (Atamna and Frey, 
2004; Atamna and Boyle, 2006).  
 Studies on heme and mitochondrial dysfunction in neuronal cells need to 
be done, as this remains an under-studied area. Does FECH blockade lead to 
reduced respiration, defective glycolysis and disruption of mitochondrial potential, 
dynamics and deformity in hippocampal and basal ganglia neurons? It would be 
beneficial to look for indicators of mitochondrial distress in Alzheimer’s patient 
tissue sections using electron microscopy or immunohistochemistry.  One critical 
challenge would be to evaluate whether heme synthesis inhibition drives AD 
pathogenesis. This could be examined by using small molecule heme inhibitors 
and by specifically targeting dopaminergic or hippocampal neurons. 
Neuroinflammatory markers like IBA-1 and GFAP can be determined in retinal 
sections of heme-deficient animal models. 
 In conclusion, my studies on heme and mitochondria inches one step 
closer to bridging the gap in heme and mitochondrial vascular biology. 
Implication of heme in the pathogenesis of neovascular and aging degenerative 
diseases is a novelty, that I hope will be explored in future studies to come. More 
importantly, my work has led to new and fetching questions, beyond the eye. 
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